



Vicente Soriano Vázquez

Generado desde: Editor CVN de FECYT

Fecha del documento: 17/09/2018

v 1.4.0

2476498e78ec462b67028f841867fcbd

Este fichero electrónico (PDF) contiene incrustada la tecnología CVN (CVN-XML). La tecnología CVN de este fichero permite exportar e importar los datos curriculares desde y hacia cualquier base de datos compatible. Listado de Bases de Datos adaptadas disponible en <http://cvn.fecyt.es/>



Resumen libre del currículum

Descripción breve de la trayectoria científica, los principales logros científico-técnicos obtenidos, los intereses y objetivos científico-técnicos a medio/largo plazo de la línea de investigación. Incluye también otros aspectos o peculiaridades importantes.

El Dr. Vicente Soriano es uno de los expertos nacionales en enfermedades infecciosas, particularmente en hepatitis y VIH. Se formó como médico en Barcelona, donde luego cursó la especialidad de Medicina Interna. Más adelante, realizó una estancia post-doctoral en Estados Unidos. En 1992 se incorporó al Hospital Carlos III de Madrid, donde lideró el grupo de investigación en enfermedades infecciosas hasta hace unos años. Las publicaciones de su grupo figuran entre las primeras en el ranking mundial de impacto científico en VIH/sida y en Hepatitis. El Dr. Soriano es actualmente el editor de AIDS Reviews y colabora en el consejo editorial de otras revistas médicas internacionales de enfermedades infecciosas. Ha sido asesor de la OMS, de la Comisión Europea y del Plan Nacional del SIDA. Actualmente es profesor de la Facultad de Ciencias de la Salud de la UNIR.

Otros méritos de investigación y científicos:

- Dirección de 31 tesis doctorales
- Índice "h" de 81 (web of science)
- Publicaciones en PubMed 1236.
- Editor jefe de la revista AIDS Reviews (impact factor 4,1). Años 1998-2018
- Editor asociado. Clinical Infectious Diseases (impact factor: 9'7). Años 2009-2015
- Miembro del Consejo editorial (editorial board) de las publicaciones científicas AIDS, JAC, HIV Clinical Trials, AIDS Research Human Retroviruses, Journal of Viral Hepatitis, HIV Medicine, Medicina Clínica, etc.
- Premio internacional a la publicación más citada en la revista AIDS en dos años distintos, concedido en las International AIDS Conferences de Johannesburgo 2008 y Sidney 2011, respectivamente.
- II Premio SOGAISIDA 2011
- Miembro de la International AIDS Society (IAS)
- Miembro de la European AIDS Clinical Society (EACS)
- Miembro del Grupo Español del SIDA (GESIDA)
- Miembro de American Society for Microbiology (ASM)
- Miembro de la Sociedad Europea de Hepatología (EASL)



Indicadores generales de calidad de la producción científica

Descripción breve de los principales indicadores de calidad de la producción científica (sexenios de investigación, tesis doctorales dirigidas, citas totales, publicaciones en primer cuartil (Q1), índice h....). Incluye también otros aspectos o peculiaridades importantes.

1236 citas en PubMed
índice "h" en web of science: 81
registros en orcid y researcherid.



Vicente Soriano Vázquez

Apellidos: **Soriano Vázquez**
 Nombre: **Vicente**
 DNI: **37740743C**
 Fecha de nacimiento: **24/11/1961**
 Sexo: **Hombre**
 Nacionalidad: **España**
 País de nacimiento: **España**
 C. Autón./Reg. de nacimiento: **Cataluña**
 Ciudad de nacimiento: **Barcelona**
 Dirección de contacto: **UNIR, Calle Almansa 101**
 Resto de dirección contacto: **Facultad de Ciencias de la Salud**
 Código postal: **28040**
 País de contacto: **España**
 Ciudad de contacto: **Madrid**
 Teléfono fijo: **(34) 915674391**
 Fax: **(34) 915674391**
 Correo electrónico: **vicente.soriano@unir.net**
 Teléfono móvil: **(34) 659687981**

Situación profesional actual

Entidad empleadora: Universidad Internacional de la Rioja (UNIR) **Tipo de entidad:** Universidad
Departamento: Ciencias de la Salud
Categoría profesional: Profesor
Fecha de inicio: 2018
Modalidad de contrato: Contrato laboral indefinido **Régimen de dedicación:** Tiempo completo
Primaria (Cód. Unesco): 320000 - Ciencias Médicas
Secundaria (Cód. Unesco): 320500 - Medicina Interna
Terciaria (Cód. Unesco): 320102 - Genética clínica; 320103 - Microbiología clínica

Cargos y actividades desempeñados con anterioridad

	Entidad empleadora	Categoría profesional	Fecha de inicio
1	Hospital Carlos III	facultativo especialista	1992
2	Food and Drug Administration (FDA), Bethesda, MD, USA	visiting fellow	1990
3	Hospital Universitario La Paz	facultativo especialista	2014

1 Entidad empleadora: Hospital Carlos III **Tipo de entidad:** Instituciones Sanitarias
Categoría profesional: facultativo especialista
Fecha de inicio-fin: 1992 - 2014 **Duración:** 22 años



- 2** **Entidad empleadora:** Food and Drug Administration (FDA), Bethesda, MD, USA
Categoría profesional: visiting fellow
Fecha de inicio-fin: 1990 - 1992 **Duración:** 2 años
- 3** **Entidad empleadora:** Hospital Universitario La Paz
Categoría profesional: facultativo especialista
Fecha de inicio: 2014 **Tipo de entidad:** Instituciones Sanitarias
Duración: 4 años



Formación académica recibida

Titulación universitaria

Estudios de 1º y 2º ciclo, y antiguos ciclos (Licenciados, Diplomados, Ingenieros Superiores, Ingenieros Técnicos, Arquitectos)

- 1 Titulación universitaria:** Doctor
Nombre del título: Doctor en Medicina
Entidad de titulación: Universitat Autònoma de Barcelona **Tipo de entidad:** Universidad
Fecha de titulación: 1990
- 2 Titulación universitaria:** Titulado Superior
Nombre del título: Licenciado en Medicina y Cirugía
Entidad de titulación: Universitat Autònoma de Barcelona **Tipo de entidad:** Universidad
Fecha de titulación: 1986

Doctorados

Programa de doctorado: Avances en Medicina Interna
Entidad de titulación: Universitat Autònoma de Barcelona **Tipo de entidad:** Universidad
Fecha de titulación: 1990

Conocimiento de idiomas

Idioma	Comprensión auditiva	Comprensión de lectura	Interacción oral	Expresión oral	Expresión escrita
Francés	C1	C1	C1	C1	C1
Inglés	C1	C1	C1	C1	C1
Catalán	C2	C2	C2	C2	C2

Actividad docente



Dirección de tesis doctorales y/o proyectos fin de carrera

- 1 Entidad de realización:** Autónoma de Madrid Facultad de Ciencias 2003 Apto cum laude • Síndrome de lipodistrofia en pacientes infectados por el VIH Teresa García Benayas
- 2 Entidad de realización:** Autónoma de Madrid Facultad de Ciencias 2007 Apto cum laude • Tropicismo del VIH-1: Metodologías diagnósticas y aplicaciones clínicas. Verónica Briz Sebastián
- 3 Entidad de realización:** Autónoma de Madrid Facultad de Medicina 2002 Apto cum laude • Influencia de la terapia antiviral en la coinfección por el VIH y el Virus de la Hepatitis C María Teresa Pérez Olmeda
- 4 Entidad de realización:** Autónoma de Madrid Facultad de Medicina 2010 Apto cum laude, Mención
- 5 Entidad de realización:** Autónoma de Madrid Facultad de Medicina 1996 Apto cum laude • Características virológicas y polimorfismo en el gen CCR5 en pacientes con progresión rápida y lenta de la infección por VIH-1 Antoni
- 6 Entidad de realización:** Autónoma de Madrid Facultad de Ciencias Químicas 1998 Apto cum laude • Evaluación y aplicación de las pruebas de carga viral ultrasensibles en los pacientes infectados por VIH Carmen de Mendoza
- 7 Entidad de realización:** Complutense de Madrid Facultad de Biología 2010 Apto cum laude • Farmacocinética y farmacogenética de la ribavirina en la respuesta al tratamiento de pacientes coinfectados VIH-VHC. Judit Morello Bul
- 8 Entidad de realización:** Complutense de Madrid Facultad de Ciencias Biológicas 2002 Apto cum laude • Estrategias de simplificación en el tratamiento de la infección por el VIH Pablo Barreiro García
- 9 Entidad de realización:** Complutense de Madrid Facultad de Farmacia 2005 Apto cum laude • Concentraciones plasmáticas de ribavirina en pacientes coinfectados VIH/VHC: factores determinantes e implicaciones clínicas Ana Lucia
- 10 Entidad de realización:** Complutense de Madrid Facultad de Farmacia 2005 Apto cum laude • Evolución de los patrones de prescripción de la terapia antirretroviral. Análisis de los factores determinantes en el Periodo 1996-200
- 11 Entidad de realización:** Complutense de Madrid Facultad de Farmacia 2006 Apto cum laude • Estudio de la respuesta inmune celular específica frente al virus de la hepatitis C en pacientes con hepatitis. Influencia del tratami
- 12 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2001 Apto cum laude • Mutaciones de resistencia en pacientes que fracasan con un régimen antirretroviral que incluye Nelfinavir Esperanza Casas García
- 13 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2003 Apto cum laude • Mutaciones de resistencias a los antirretrovirales en pacientes infectados por VIH-1: implicaciones clínicas y epidemiológicas Oscar G



- 14 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2004 Apto cum laude • Análisis de la respuesta inmune mediada por linfocitos T CD8+ en pacientes con infección crónica por VIH María de la O López Vázquez d
- 15 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2004 Apto cum laude • Evolución virológica e inmunológica en pacientes VIH+ expuestos a Enfuvirtida, un inhibidor de la fusión del VIH Eva Poveda López
- 16 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2004 Apto cum laude • Impacto de la coinfección del virus de la hepatitis C en pacientes infectados por el VIH Luz Martín Carbonero
- 17 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2004 Apto cum laude • Infección por HTLV-2 en España: características epidemiológicas e implicaciones diagnósticas y patogénicas Sylvina Bassani Castellanos
- 18 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2005 Apto cum laude • Factores predictores de respuesta virológica a combinaciones de rescate con inhibidores de la proteasa potenciados con ritonavir en pa
- 19 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2007 Apto cum laude • Caracterización de las secuencias largas terminales repetidas (LTRs) en diferentes variantes del VIH-1. Eva Ramírez de Arellano
- 20 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2008 Apto cum laude • Caracterización funcional de la respuesta inmune celular frente al virus de la hepatitis C (VHC) en pacientes coinfectados VIH/VHC. As
- 21 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2010 Apto cum laude • Caracterización genética de la integrasa del VIH y su impacto clínico en el tratamiento con inhibidores de la integrasa. Carolina G
- 22 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2013 Apto cum laude • Resistencia a los nuevos antivirales frente al virus de la hepatitis C Zulema Plaza Calvo
- 23 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2011 Apto cum laude • Infección por HTLV en España: Seroprevalencia, inmunopatogenia y factores pronósticos. Ana Treviño Rodríguez---Casanova
- 24 Entidad de realización:** Complutense de Madrid Facultad de Ciencias Biológicas 1997 Apto cum laude • Significado clínico de las mutaciones en el genoma del VIH-1 asociadas a resistencias a nucleósidos María Gómez-Cano Alfa
- 25 Entidad de realización:** Complutense de Madrid Facultad de Ciencias Biológicas 2000 Apto cum laude • Prevalencia y predictores de trastornos psiquiátricos en pacientes infectados por el Virus de la Inmunodeficiencia Human
- 26 Entidad de realización:** Complutense de Madrid Facultad de Ciencias Biológicas 2000 Apto cum laude • Infección por VIH-2, HTLV-I y HTLV-II en España Ana Machuca



- 27 Entidad de realización:** Complutense de Madrid. Facultad de Medicina. Departamento de Microbiología I, 2009 Apto cum laude • Desarrollo de un índice pronóstico de la respuesta del VHC a peginterferón/ribavirina, ponderado p
- 28 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2012 Apto cum laude - Infección oculta por el virus de la hepatitis B Antonio González del Castillo
- 29 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2014 Apto cum laude • Epidemiología de las resistencia a los antivirales en el virus de la hepatitis C Isabella Esposito
- 30 Entidad de realización:** El Dr. Soriano ha dirigido 27 tesis doctorales a licenciados de Medicina, Biología, Química y Farmacia. Seis de ellas han recibido la nominación de premio extraordinario. • Eficacia y tolerancia de
- 31 Entidad de realización:** de Napoles Facultad de Medicina 2015 Apto cum laude Apto cum laude
- 32 Entidad de realización:** Complutense de Madrid Facultad de Medicina 2012 Apto cum laude • Diagnóstico y epidemiología de la infección por el nuevo retrovirus humano XMRV en diferentes grupos de
Ciudad entidad realización: en España Miguel Arredondo Calvo,

Actividad sanitaria

Actividad sanitaria en instituciones de la UE

Resultados relevantes: Miembro del Panel Evaluador de Proyectos de la Comisión Europea (2008-2012)

Entidad de realización: Comisión Europea

Tipo de entidad: P

Actividad sanitaria en la OMS

1 Resultados relevantes: Asesor del Panel de VIH-SIDA de la OMS (2006-2010)

Entidad de realización: OMS

2 Resultados relevantes: Miembro del Panel de Expertos de Hepatitis de la OMS (2009-2012)

Entidad de realización: OMS



Experiencia científica y tecnológica

Resultados

Propiedad industrial e intelectual

Productos: - El índice Prometheus (<http://ideasydesarrollo.com/fundacion/prometheusindex.php>), herramienta diseñada para predecir la respuesta al tratamiento en la hepatitis C que se ha publicado en la revista Clinical Infectious Diseases (Medrano J, Neukam K, Rallón N, Rivero A, Resino S, Naggie S, Caruz A, Calvino A, Macías J, Benito JM, Sánchez-Piedra C, Vispo E, Barreiro P, McHutchison J, Pineda JA, Soriano V. Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. Clin Infect Dis 2010; 10:727-34).; 11:39-51) - También se ha patentado un método fenotípico para la detección de mutantes a antivirales en el virus de la hepatitis B (VHB) (Sheldon J, Camino N, Rodés B, Bartholomeusz A, Kuiper M, Tacke F, Núñez M, Mauss S, Lutz T, Klausen G, Locarnini S, Soriano V. Selection of hepatitis B virus polymerase mutations in HIV-coinfecting patients treated with tenofovir. Antivir Ther 2005; 51:1209-16), - El desarrollo de un algoritmo diagnóstico para la determinación del tropismo viral del VIH-1, utilizado para orientar el tratamiento con antagonistas de CCR5 (Poveda E, Seclén E, González Mdel M, García F, Chueca N, Aguilera A, Rodríguez JJ, González-Lahoz J, Soriano V. Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 2009; 63:1006-10). - El algoritmo de interpretación de resistencias del VIH a los antirretrovirales. Anualmente la plataforma de resistencias de la red de SIDA (RIS) liderada por el Dr. Soriano, elabora y revisa las guías españolas de interpretación de resistencias del VIH a los antirretrovirales. Estas guías cuentan con un algoritmo disponible en la web www.retic-ris.net, una publicación anual en español y han sido además publicadas en la revista AIDS Reviews (de Mendoza C, Anta L, García F, Pérez-Elías MJ, Gutiérrez F, Llibre JM, Menéndez-Arias L, Dalmau D, Soriano V. HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. AIDS Rev 2009

Actividades científicas y tecnológicas

Producción científica

Publicaciones, documentos científicos y técnicos

- 1 HIV and the Liver. 2011.
Tipo de producción: Libro o monografía científica **Tipo de soporte:** Libro
- 2 Update on HIV and HCV coinfection. 2010.
Tipo de producción: Libro o monografía científica **Tipo de soporte:** Libro
- 3 Antiviral combination therapy for treatment of chronic hepatitis B, hepatitis C, and human immunodeficiency virus infection. 2009.
Tipo de producción: Libro o monografía científica **Tipo de soporte:** Libro



- 4** Human Immunodeficiency Virus and the Liver. 2008.
Tipo de producción: Libro o monografía científica **Tipo de soporte:** Libro
- 5** AIDS Clinical Research in Spain Large HIV Population, Geniality of Doctors, and Missing Opportunities. 2018.
- 6** Decline and changing profile of hepatitis delta among injection drug users in Spain. 2018.
- 7** Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study. 2018.
- 8** Prevention of liver cancer with new curative hepatitis C antivirals: Real-world challenges. 2018.
- 9** A New HIV Paradigm: Dual Antiretroviral Regimens as Maintenance Therapy. 2017.
- 10** CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: A multinational, multicohort European study. 2017.
- 11** Drug interactions in HIV-infected patients treated for hepatitis C. 2017.
- 12** Drug resistance mutations in HIV-2 patients failing raltegravir and influence on dolutegravir response. 2017.
- 13** Dual antiretroviral therapy for HIV infection. 2017.
- 14** Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C. 2017.
- 15** HIV type 2 epidemic in Spain: Challenges and missing opportunities. 2017.
- 16** Hepatitis A Outbreaks in European Homosexual Men. 2017.
- 17** Human T-Lymphotropic Virus Infection in Hepatitis C Virus-Antibody Positive Patients in Spain. 2017.



- 18 Human T-lymphotropic virus type 1 infection and disease in Spain. 2017.
- 19 Impact of ITPA gene polymorphisms on the risk of ribavirin-induced haemolytic anaemia using interferon-free antivirals for chronic hepatitis C. 2017.
- 20 Infection with the human T-cell lymphotropic virus in Spain - 30 years of evolution (1986-2016), Infección por el virus linfotrópico de células T humano en España - 30 años de evolución (1986-2016). 2017.
- 21 Is Ribavirin Teratogenic in Humans? No Evidence So Far. 2017.
- 22 Need to Face Liver Cirrhosis after HCV Cure with Antivirals. 2017.
- 23 Prediction of long-term outcomes of HIV-infected patients developing non-AIDS events using a multistate approach. 2017.
- 24 Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials. 2017.
- 25 Transmission of Multi-Drug Resistant HIV-1 Despite Antiretroviral Prophylaxis. 2017.
- 26 Acute hepatitis C virus re-infection in a heterosexual HIV-positive partner. 2016.
- 27 Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: Raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. 2016.
- 28 Faldaprevir, deleobuvir and ribavirin in IL28B non-CC patients with HCV genotype-1a infection included in the SOUND-C3 phase 2b study. 2016.
- 29 Hepatitis C virus coinfection independently increases the risk of cardiovascular disease in HIV-positive patients. 2016.
- 30 Hepatitis C virus resistance to the new direct-acting antivirals. 2016.
- 31 High serum HCV RNA in chronic hepatitis C patients coinfecting with HIV despite successful antiretroviral therapy. 2016.



- 32 Host and disease factors are associated with cognitive function in European HIV-infected adults prior to initiation of antiretroviral therapy. 2016.
- 33 Human T-lymphotropic virus 1 (HTLV-1) and human T-lymphotropic virus 2 (HTLV-2): Geographical research trends and collaboration networks (1989-2012). 2016.
- 34 Hypoglycemia in a diabetic patient during hepatitis C therapy. 2016.
- 35 IL15 polymorphism is associated with advanced fibrosis, inflammation-related biomarkers and virological response in human immunodeficiency virus/hepatitis C virus coinfection. 2016.
- 36 Impact of late presentation of HIV infection on short-, mid- and long-term mortality and causes of death in a multicenter national cohort: 2004-2013. 2016.
- 37 Infection-related and -unrelated malignancies, HIV and the aging population. 2016.
- 38 Is HIV still a special population for the treatment of hepatitis C?. 2016.
- 39 MicroRNA profile in CD8+ T-lymphocytes from HIV-infected individuals: Relationship with antiviral immune response and disease progression. 2016.
- 40 Prevention and management of treatment failure to new oral hepatitis C drugs. 2016.
- 41 Reactivation of Hepatitis B in HIV Patients Treated for Hepatitis C. 2016.
- 42 Relationship of TRIM5 and TRIM22 polymorphisms with liver disease and HCV clearance after antiviral therapy in HIV/HCV coinfecting patients. 2016.
- 43 Report from the international conference on viral hepatitis (ICVH), San Francisco, march 2016. 2016.
- 44 SOLAR-2: the sun also rises for cirrhotics. 2016.
- 45 Short communication: CXCL12 rs1029153 polymorphism is associated with the sustained virological response in HIV/Hepatitis C virus-coinfecting patients on Hepatitis C Virus therapy. 2016.



- 46 The global spread of HIV-1 subtype B epidemic. 2016.
- 47 Advances in treating drug-resistant hepatitis B virus in HIV-infected patients. 2015.
- 48 Caution with new oral hepatitis C drugs. 2015.
- 49 Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study. 2015.
- 50 Circulating microRNAs in sera correlate with soluble biomarkers of immune activation but do not predict mortality in ART treated individuals with HIV-1 infection: A case control study. 2015.
- 51 Correction: Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. 2015.
- 52 Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. 2015.
- 53 Differences in the availability of diagnostics and treatment modalities for chronic hepatitis B across Europe. 2015.
- 54 Dual antiviral therapy for HIV and hepatitis C - Drug interactions and side effects. 2015.
- 55 Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis. 2015.
- 56 Extrahepatic comorbidities associated with hepatitis C virus in HIV-infected patients. 2015.
- 57 Faldaprevir and pegylated interferon α -2a/ribavirin in individuals co-infected with hepatitis C virus genotype-1 and HIV. 2015.
- 58 Gene therapy for HIV infection. 2015.
- 59 Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis. 2015.



- 60 Hepatic safety in subjects with HIV-1 and hepatitis C and/or B virus: A randomized, double-blind study of maraviroc versus placebo in combination with antiretroviral agents. 2015.
- 61 ITPA genotypes predict anemia but do not affect virological response with interferon-free faldaprevir, deleobuvir, and ribavirin for HCV infection. 2015.
- 62 Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study. 2015.
- 63 Non-human cancers in AIDS patients. 2015.
- 64 Prioritization of new oral hepatitis C therapies for HIV patients. 2015.
- 65 Rate and predictors of serum HCV-RNA >6 million IU/mL in patients with chronic hepatitis C. 2015.
- 66 TLR3 polymorphisms are associated with virologic response to hepatitis C virus (HCV) treatment in HIV/HCV coinfecting patients. 2015.
- 67 The burden of neglected HIV-2 and HTLV-1 infections in Spain. 2015.
- 68 Transmitted drug resistance to rilpivirine in newly diagnosed antiretroviral naive adults. 2015.
- 69 Use of cohort data to estimate national prevalence of transmitted drug resistance to antiretroviral drugs in Spain (2007-2012). 2015.
- 70 A polymorphism linked to RRAS, SCAF1, IRF3 and BCL2L12 genes is associated with cirrhosis in hepatitis C virus carriers. 2014.
- 71 A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. 2014.
- 72 ACSM4 Polymorphisms Are Associated With Rapid AIDS Progression in HIV-Infected Patients. 2014.
- 73 Changes in liver fibrosis in HIV/HCV-coinfecting patients following different outcomes with peginterferon plus ribavirin therapy. 2014.



- 74** Diagnosis of subclinical atherosclerosis in HIV-infected patients: Higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms. 2014.
- 75** Dolutegravir, abacavir and lamivudine as HIV therapy. 2014.
- 76** Emerging antiretroviral drugs. 2014.
- 77** European mitochondrial haplogroups are not associated with hepatitis C virus (HCV) treatment response in HIV/HCV-coinfected patients. 2014.
- 78** Genome-wide mRNA and miRNA analysis of peripheral blood mononuclear cells (PBMC) reveals different miRNAs regulating HIV/HCV co-infection. 2014.
- 79** HIV-2 and HTLV-1 infections in Spain, a non-endemic region. 2014.
- 80** HIV-2 viral tropism influences CD4+ T cell count regardless of viral load. 2014.
- 81** Hepatitis E: An emerging viral disease, Hepatitis E: una enfermedad viral emergente. 2014.
- 82** IFNL4 ss469415590 variant shows similar performance to rs12979860 as predictor of response to treatment against hepatitis C virus genotype 1 or 4 in Caucasians. 2014.
- 83** Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe. 2014.
- 84** Incidence of Hepatitis C Virus (HCV) in a multicenter cohort of HIV-positive patients in Spain 2004-2011: Increasing rates of HCV diagnosis but not of HCV seroconversions. 2014.
- 85** Infections due to human immunodeficiency virus type 2 and human T-lymphotropic viruses in Spain, Infecciones por el virus de la inmunodeficiencia humana tipo 2 y por los virus linfotrópicos de células T humanas en España. 2014.
- 86** Liver fibrosis progression in HIV-HCV-coinfected patients treated with distinct antiretroviral drugs and impact of pegylated interferon/ribavirin therapy. 2014.
- 87** Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries. 2014.



- 88 PPAR γ 2 Pro12Ala polymorphism is associated with sustained virological response in HIV/HCV-coinfected patients under HCV therapy. 2014.
- 89 RNA viruses at the forefront of human infections - HIV, hepatitis C, and now Ebola. 2014.
- 90 Spontaneous hepatitis C virus clearance in HIV patients with chronic hepatitis C bearing IL28B-CC alleles using antiretroviral therapy. 2014.
- 91 Sustained virological response in HIV/HCV co-infected patients treated with pegylated interferon/ribavirin can be predicted from the overall rate of viral load decline over the first 4 weeks of therapy. 2014.
- 92 Tuberculosis in a cohort of HIV-positive patients: Epidemiology, clinical practice and treatment outcomes. 2014.
- 93 X4 tropic viruses are on the rise in recent HIV-1 seroconverters in Spain. 2014.
- 94 A model to predict the response to therapy against hepatitis C virus (HCV) including low-density lipoprotein receptor genotype in HIV/HCV-coinfected patients. 2013.
- 95 Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients. 2013.
- 96 Antiretroviral drug-related toxicities - clinical spectrum, prevention, and management. 2013.
- 97 Central memory CD4 T cells are associated with incomplete restoration of the CD4 T cell pool after treatment-induced long-term undetectable HIV viraemia. 2013.
- 98 Chronic hepatitis e in HIV patients: Rapid progression to cirrhosis and response to oral ribavirin. 2013.
- 99 Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV?. 2013.
- 100 Effects of the genetic pattern defined by low-density lipoprotein receptor and IL28B genotypes on the outcome of hepatitis C virus infection. 2013.
- 101 Erratum: Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients (AIDS (2011) 25 (761-766)). 2013.



- 102** Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. 2013.
- 103** HIV exposed seronegative individuals show antibodies specifically recognizing native HIV envelope glycoprotein. 2013.
- 104** HLA-E variants are associated with sustained virological response in HIV/hepatitis C virus-coinfected patients on hepatitis C virus therapy. 2013.
- 105** Healthcare resources restrictions and human immunodeficiency virus infection, Recortes sanitarios e infección por el virus de la inmunodeficiencia humana. 2013.
- 106** Hepatitis B in HIV-infected patients. 2013.
- 107** Hepatitis B, C, and D and HIV infections among immigrants from equatorial guinea living in Spain. 2013.
- 108** Hepatitis C therapy with HCV NS5B polymerase inhibitors. 2013.
- 109** Hepatitis C therapy: Highlights from the 2012 annual meeting of the european association for the study of the liver. 2013.
- 110** Hepatitis C virus genotype 4 in Southern and Central Spain does not originate from recent foreign migration waves. 2013.
- 111** Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. 2013.
- 112** IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients. 2013.
- 113** Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. 2013.
- 114** Liver stiffness predicts liver-related complications and mortality in HIV patients with chronic hepatitis C on antiretroviral therapy. 2013.
- 115** Longitudinal changes in viral RNA concentration in patients with chronic hepatitis C and/or HIV infection in the absence of antiviral therapy. 2013.



- 116** Low risk of liver toxicity using the most recently approved antiretroviral agents but still increased in HIV-hepatitis C virus coinfecting patients. 2013.
- 117** Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: A cohort study. 2013.
- 118** Pegylated interferon plus ribavirin is suboptimal in IL28B CC carriers without rapid response. 2013.
- 119** Pharmacokinetics of new oral hepatitis C antiviral drugs. 2013.
- 120** Resistance to the most recent protease and non-nucleoside reverse transcriptase inhibitors across HIV-1 non-B subtypes. 2013.
- 121** Rilpivirine resistance mutations in HIV patients failing non-nucleoside reverse transcriptase inhibitor-based therapies. 2013.
- 122** Risk, predictors, and mortality associated with non-AIDS events in newly diagnosed HIV-infected patients: Role of antiretroviral therapy. 2013.
- 123** Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study. 2013.
- 124** Scaling up epidemics of acute hepatitis C and syphilis in HIV-infected men who have sex with men in Spain. 2013.
- 125** Sensitive cell-based assay for determination of human immunodeficiency virus type 1 coreceptor tropism. 2013.
- 126** Stability of hepatitis C virus (HCV) RNA levels among interferon-naïve HIV/HCV-coinfecting individuals treated with combination antiretroviral therapy. 2013.
- 127** Strategic use of lamivudine in the management of chronic hepatitis B. 2013.
- 128** Temporal changes and regional differences in treatment uptake of hepatitis C therapy in EuroSIDA. 2013.
- 129** The changing epidemiology of liver disease in HIV patients. 2013.



- 130** The changing face of hepatitis C in the new era of direct-acting antivirals. 2013.
- 131** Treatment of hepatitis C in HIV patients in the new era of direct-acting antivirals. 2013.
- 132** Triple combination therapy for hepatitis C with telaprevir exhibits greater early antiviral activity than with boceprevir. 2013.
- 133** Update on HIV/HCV coinfection. 2013.
- 134** Variations at multiple genes improve interleukin 28B genotype predictive capacity for response to therapy against hepatitis C infection. 2013.
- 135** A New Era for Hepatitis C-New Diagnostics Tools and New Weapons. 2012.
- 136** Antiretroviral Drugs for Pre-Exposure Prophylaxis of HIV Infection. 2012.
- 137** Antiviral effect of raltegravir on HTLV-1 carriers. 2012.
- 138** Author's response: Expert reviews: Who are they for?. 2012.
- 139** Broad phenotypic cross-resistance to elvitegravir in HIV-infected patients failing on raltegravir-containing regimens. 2012.
- 140** Cardiovascular disease risk in HIV infection and endothelial progenitor cells. 2012.
- 141** Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. 2012.
- 142** Comparison of HIV-1 RNA measurements obtained by using plasma and dried blood spots in the automated abbott real-time viral load assay. 2012.
- 143** Comparison of high ribavirin induction versus standard ribavirin dosing, plus peginterferon-for the treatment of chronic hepatitis C in HIV-infected patients: The PERICO trial. 2012.



- 144** Development of tropical spastic paraparesis in human T-lymphotropic virus type 1 carriers is influenced by interleukin 28B gene polymorphisms. 2012.
- 145** Differences in virological response to peginterferon-a plus ribavirin in HIV-positive patients coinfecting with HCV subtypes 1a or 1b. 2012.
- 146** Different impact of IL28B polymorphisms on response to peginterferon- α plus ribavirin in HIV-positive patients infected with HCV subtypes 1a or 1b. 2012.
- 147** Drug resistance testing in hepatitis C therapy. 2012.
- 148** Efficacy and safety of rilpivirine in treatment-naive, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the phase III randomized, double-blind ECHO and THRIVE trials. 2012.
- 149** Emerging viral infections - A potential threat for blood supply in the 21st century. 2012.
- 150** Endothelial dysfunction in HIV infection - The role of circulating endothelial cells, microparticles, endothelial progenitor cells and macrophages. 2012.
- 151** HIV and liver disease. 2012.
- 152** Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients. 2012.
- 153** Highlights from the 2012 International Symposium on HIV & Emerging Infectious Diseases (ISHEID): from cART management to the search of an HIV cure. 2012.
- 154** Impact of IL28b gene polymorphisms on interferon- λ 3 plasma levels during pegylated interferon- α /ribavirin therapy for chronic hepatitis C in patients coinfecting with HIV. 2012.
- 155** Infection by HIV-2, HTLV and new human retroviruses in Spain, Infección por el VIH-2, virus linfotrópico de células T y nuevos retrovirus humanos en España. 2012.
- 156** Inpatient and outpatient pharmacokinetic variability of raltegravir in the clinical setting. 2012.
- 157** Long-term use of atazanavir in the treatment of HIV-infected patients. 2012.



- 158** Management and treatment of chronic hepatitis C in HIV patients. 2012.
- 159** Management of hepatitis C in HIV and/or HBV co-infected patients. 2012.
- 160** Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir. 2012.
- 161** Mechanisms involved in CD4 cell gains in HIV-infected patients switched to raltegravir.2012.
- 162** No influence of antiretroviral therapy on the mutation rate of the HCV NS5B polymerase in HIV/HCV-coinfected patients. 2012.
- 163** Pharmacogenetics of hepatitis C. 2012.
- 164** Phylogeographical footprint of colonial history in the global dispersal of human immunodeficiency virus type 2 group A. 2012.
- 165** Plasma raltegravir exposure influences the antiviral activity and selection of resistance mutations. 2012.
- 166** Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain. 2012.
- 167** Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. 2012.
- 168** Prevalence and risk factors associated with pulmonary hypertension in HIV-infected patients on regular follow-up. 2012.
- 169** Prevalence of natural polymorphisms at the HCV NS5A gene associated with resistance to daclatasvir, an NS5A inhibitor. 2012.
- 170** Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain. 2012.
- 171** Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study. 2012.



- 172** Rilpivirine: A next-generation non-nucleoside analogue for the treatment of HIV infection. 2012.
- 173** Short communication high risk of endothelial dysfunction in HIV individuals may result from deregulation of circulating endothelial cells and endothelial progenitor cells. 2012.
- 174** Short communication: Does interleukin-28b single nucleotide polymorphisms influence the natural history of hepatitis b?. 2012.
- 175** Short communication: RNASEL alleles and susceptibility to infection by human retroviruses and hepatitis viruses. 2012.
- 176** Treatment failure with new hepatitis C drugs. 2012.
- 177** Treatment of Hepatitis C in Patients Infected with Human Immunodeficiency Virus in the Direct-Acting Antiviral Era. 2012.
- 178** Treatment-associated polymorphisms in protease are significantly associated with higher viral load and lower CD4 count in newly diagnosed drug-naive HIV-1 infected patients. 2012.
- 179** Use of raltegravir in distinct clinical scenarios. 2012.
- 180** Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia in HIV/HCV-coinfected patients with All HCV genotypes. 2012.
- 181** A Highly Sensitive and Specific Model for Predicting HIV-1 Tropism in Treatment-Experienced Patients Combining Interpretation of V3 Loop Sequences and Clinical Parameters. 2011.
- 182** A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. 2011.
- 183** Acute hepatitis C in HIV-infected individuals: recommendations from the European AIDS Treatment Network (NEAT) consensus conference The European AIDS Treatment Network (NEAT) Acute Hepatitis C Infection Consensus Panel. 2011.
- 184** An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHI(E)V(2E) Quality Control Study. 2011.
- 185** An international collaboration to standardize HIV-2 viral load assays: Results from the 2009 ACHI<inf>E</inf>V<inf>2E</inf>quality control study. 2011.



- 186** An update on the atazanavir, ritonavir, tenofovir, emtricitabine and nevirapine (ARTEN) trial. 2011.
- 187** Approaches for understanding and predicting drug interactions in human immunodeficiency virus-infected patients. 2011.
- 188** Association between IL28B gene polymorphisms and plasma HCV-RNA levels in HIV/HCV-co-infected patients. 2011.
- 189** Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients. 2011.
- 190** Changing rate of non-B subtypes and coinfection with hepatitis B/C viruses in newly diagnosed HIV type 1 individuals in Spain. 2011.
- 191** Characterization of host genetic expression patterns in HIV-infected individuals with divergent disease progression. 2011.
- 192** Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. 2011.
- 193** Critical appraisal and update on tenofovir in management of human immunodeficiency virus infection. 2011.
- 194** Detection of hepatitis B virus genotype A3 and primary drug resistance mutations in African immigrants with chronic hepatitis B in Spain. 2011.
- 195** Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype. 2011.
- 196** Directly acting antivirals against hepatitis C virus. 2011.
- 197** Drug resistance mutations in patients infected with HIV-2 living in Spain. 2011.
- 198** Elevated TGF- β 1 levels might protect HCV/HIV-coinfected patients from liver fibrosis. 2011.
- 199** Elite controllers display higher activation on central memory CD8 T cells than HIV patients successfully on HAART. 2011.



- 200** European guidelines on the clinical management of HIV-1 tropism testing. 2011.
- 201** European recommendations for the clinical use of HIV drug resistance testing: 2011 update. 2011.
- 202** Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction. 2011.
- 203** HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. 2011.
- 204** HCV and HIV coinfection. 2011.
- 205** HCV-specific T-Cell responses in HIV/Hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals. 2011.
- 206** HTLV infection among foreign pregnant women living in Spain. 2011.
- 207** Hepatitis C virus (HCV) treatment uptake and changes in the prevalence of HCV genotypes in HIV/HCV-coinfected patients. 2011.
- 208** Hepatitis delta in HIV-infected individuals in Europe. 2011.
- 209** High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. 2011.
- 210** Host factors involved in low susceptibility to HIV infection. 2011.
- 211** Host genetics. 2011.
- 212** Hot news news from the 2011 coinfection workshop. 2011.
- 213** Human immunodeficiency virus infection and viral hepatitis, Infección por virus de la inmunodeficiencia humana y hepatitis víricas. 2011.



- 214** Hyaluronic acid levels predict increased risk of non-AIDS death in hepatitis-coinfected persons interrupting antiretroviral therapy in the SMART study. 2011.
- 215** Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naïve HIV-2-infected patients: The ACHI<inf>EV</inf>2E collaboration study group. 2011.
- 216** Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients. 2011.
- 217** Impact of baseline HIV-1 tropism on viral response and CD4 cell count gains in HIV-infected patients receiving first-line antiretroviral therapy. 2011.
- 218** Impact of inosine triphosphatase gene variants on the risk of anemia in HIV/Hepatitis C virus-coinfected patients treated for chronic hepatitis C. 2011.
- 219** Influence of interleukin-28B single-nucleotide polymorphisms on progression to liver cirrhosis in human immunodeficiency virus-hepatitis C virus-coinfected patients receiving antiretroviral therapy. 2011.
- 220** Interleukin-28B gene polymorphisms do not influence the susceptibility to HIV-infection or CD4 cell decline. 2011.
- 221** Lipid profiles for nevirapine vs. atazanavir/ritonavir, both combined with tenofovir disoproxil fumarate and emtricitabine over 48 weeks, in treatment-naïve HIV-1-infected patients (the ARTEN study). 2011.
- 222** Long-term non-progressors display a greater number of Th17 cells than HIV-infected typical progressors. 2011.
- 223** Longitudinal assessment of interleukin 7 plasma levels in HIV-infected patients in the absence of and under antiretroviral therapy. 2011.
- 224** Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients. 2011.
- 225** Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naïve HIV-1 patients: The ARTEN Trial. 2011.
- 226** New 2011 updated DHHS antiretroviral treatment guidelines and chronic hepatitis B. 2011.
- 227** Noncirrhotic portal hypertension in HIV infection. 2011.



- 228** Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: A useful tool in the multitarget era of antiretroviral therapy. 2011.
- 229** Preexposure prophylaxis in the prevention of HIV infection, Profilaxis preexposición en la prevención de la infección por virus de la inmunodeficiencia humana. 2011.
- 230** Resistance associated mutations to dolutegravir (S/GSK1349572) in HIV-infected patients - Impact of HIV subtypes and prior raltegravir experience. 2011.
- 231** Resistance data in the ARTEN trial [2]. 2011.
- 232** Response to: Is the study power enough to say 'no difference'? by Geib et al. 2011.
- 233** Risk factors for advanced liver fibrosis in HIV-infected individuals: Role of antiretroviral drugs and insulin resistance. 2011.
- 234** Seroprevalence of HTLV infection among immigrant pregnant women in the Mediterranean coast of Spain. 2011.
- 235** Short communication: Severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions. 2011.
- 236** Short communication: Use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy. 2011.
- 237** Soluble markers of inflammation are associated with Framingham scores in HIV-infected patients on suppressive antiretroviral therapy. 2011.
- 238** The expansion ability but not the quality of HIV-specific CD8⁺ T cells is associated with protective human leucocyte antigen class I alleles in long-term non-progressors. 2011.
- 239** The state of hepatitis B and C in Europe: Report from the hepatitis B and C summit conference. 2011.
- 240** Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis. 2011.
- 241** XMRV, a new human retrovirus for disease, XMRV, un nuevo retrovirus humano en busca de enfermedad. 2011.



- 242** [Future perspective in the treatment of chronic hepatitis C].,Perspectivas futuras en el tratamiento de la hepatitis crónica C.2011.
- 243** Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients. 2010.
- 244** Current situation of human immunodeficiency virus type 2 and Human T lymphotropic virus in Spain,Situación actual de la infección por el virus de la inmunodeficiencia humana tipo 2 y el Virus linfotrópico de células T humano en España. 2010.
- 245** Dialysis and renal transplantation in HIV-infected patients: A European survey. 2010.
- 246** Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes. 2010.
- 247** Drastic decrease of transcription activity due to hypermutated long terminal repeat (LTR) region in different HIV-1 subtypes and recombinants. 2010.
- 248** Drug resistance mutations in HIV-infected patients in the Spanish drug resistance database failing tipranavir and darunavir therapy. 2010.
- 249** Dynamics of HIV tropism under suppressive antiretroviral therapy: Implications for tropism testing in subjects with undetectable viraemia. 2010.
- 250** Editorial: New human retrovirus,Editorial: Nuevos retrovirus humanos. 2010.
- 251** Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. 2010.
- 252** European guideline for the management of hepatitis B and C virus infections, 2010. 2010.
- 253** Evolution of the functional profile of HIV-specific CD8 + T cells in patients with different progression of HIV infection over 4 years. 2010.
- 254** Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. 2010.
- 255** Genotype testing to determine HIV coreceptor tropism. 2010.



- 256** HIV-2 and HTLV-1/2 infections in Spain, Infección por el virus de la inmunodeficiencia humana de tipo 2 (VIH-2) y los virus linfotrópico humano de células T de tipos 1 y 2 (HTLV-1/2) en España. 2010.
- 257** High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor. 2010.
- 258** High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. 2010.
- 259** High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists-authors' response. 2010.
- 260** Highlights from the 12th European AIDS Conference/European AIDS Clinical Society (EACS) Cologne, Germany, November 11-14, 2009. 2010.
- 261** Human immunodeficiency virus and liver disease: Conference proceedings. 2010.
- 262** Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrations. 2010.
- 263** Incidence of liver cirrhosis in HIV-infected patients with chronic hepatitis B or C in the era of highly active antiretroviral therapy. 2010.
- 264** Influence of a single nucleotide polymorphism at the main ribavirin transporter gene on the rapid virological response to pegylated interferon-ribavirin therapy in patients with chronic hepatitis C virus infection. 2010.
- 265** Low-level exposure to HIV induces virus-specific T cell responses and immune activation in exposed HIV-seronegative individuals. 2010.
- 266** Management of metabolic complications and cardiovascular risk in HIV-infected patients. 2010.
- 267** Modeling the probability of sustained virological response to therapy with pegylated interferon plus ribavirin in patients coinfecting with hepatitis C virus and HIV. 2010.
- 268** New paradigms for treating hepatitis B in HIV/hepatitis B virus co-infected patients. 2010.
- 269** Noncirrhotic portal hypertension in HIV-infected patients: Unique clinical and pathological findings. 2010.



- 270** Optimizing management of treatment-naïve and treatment-experienced HIV+ patients: The role of maraviroc. 2010.
- 271** Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. 2010.
- 272** Population pharmacokinetic modeling of the association between 63396C→T pregnane X receptor polymorphism and unboosted atazanavir clearance. 2010.
- 273** Predictors of hepatitis B virus genotype and viraemia in HIV-infected patients with chronic hepatitis B in Europe. 2010.
- 274** Preemptive erythropoietin plus high ribavirin doses to increase rapid virological responses in HIV patients treated for chronic hepatitis C. 2010.
- 275** Prevalence of HTLV-1/2 infections in Spain: A cross-sectional hospital-based survey. 2010.
- 276** Primary resistance to maraviroc in a large set of R5-V3 viral sequences from HIV-1-infected patients. 2010.
- 277** Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C virus coinfecting patients with prior nonresponse or relapse. 2010.
- 278** Renal toxicity associated with tenofovir use. 2010.
- 279** Safety and efficacy of tenofovir/emtricitabine plus nevirapine in HIV-infected patients. 2010.
- 280** Simplification from protease inhibitors to once-or twice-daily raltegravir: The ODIS trial. 2010.
- 281** Survival of HIV-infected patients with compensated liver cirrhosis. 2010.
- 282** The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring. 2010.
- 283** Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. 2010.



- 284** Use of the HCP5 single nucleotide polymorphism to predict hypersensitivity reactions to abacavir: correlation with HLA-B*5701. 2010.
- 285** Viral hepatitis and HIV co-infection. 2010.
- 286** (Enfermedades Infecciosas y Microbiología Clínica (2009) 27, 4, (222-235)). 2009.
- 287** Changes in drug resistance patterns following the introduction of HIV type 1 non-B subtypes in Spain. 2009.
- 288** Clinical differences and viral diversity between newly HIV type 1-diagnosed African and non-African patients in Spain (2005-2007).2009.
- 289** Correlation between human immunodeficiency virus type 1 (HIV-1) RNA measurements obtained with dried blood spots and those obtained with plasma by use of Nuclisens EasyQ HIV-1 and Abbott RealTime HIV load tests. 2009.
- 290** Delayed diagnosis of HIV infection in a multicenter cohort: Prevalence, risk factors, response to HAART and impact of mortality. 2009.
- 291** Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. 2009.
- 292** Differences in lopinavir plasma concentrations comparing Kaletra® film coated tablets and soft gelatine capsules that result in various lipid abnormalities. 2009.
- 293** First HAART in HIV-infected patients with high viral load: Value of HIV RNA levels at 12 weeks to predict virologic outcome. 2009.
- 294** Fosamprenavir (GW433908)/ritonavir in HIV-infected patients: efficacy and safety results from the Spanish Expanded Access Program. 2009.
- 295** Fosamprenavir/ritonavir in advanced HIV disease (TRIAD): A randomized study of high-dose, dual-boosted or standard dose fosamprenavir/ritonavir in HIV-1-infected patients with antiretroviral resistance. 2009.
- 296** Fourth HIV & hepatitis coinfection workshop; June 19-21, 2008; Madrid, Spain. 2009.
- 297** HIV protease inhibitors: Recent clinical trials and recommendations on use. 2009.



- 298** HIV-1 genotypic drug resistance interpretation rules - 2009 Spanish guidelines. 2009.
- 299** Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. 2009.
- 300** Hepatitis B in HIV patients: What is the current treatment and what are the challenges?. 2009.
- 301** Hepatitis C virus coinfection does not influence the CD⁴ cell recovery in HIV-1-infected patients with maximum virologic suppression. 2009.
- 302** Human immunodeficiency virus type 2 and human T-cell lymphotropic virus type 1 and type 2 infections in Spain: An update, Actualización sobre las infecciones por el virus de la inmunodeficiencia humana de tipo 2 y por los virus linfotrópico humano de tipo 1 y de tipo 2 en España. 2009.
- 303** Improvement in the determination of HIV-1 tropism using the V3 gene sequence and a combination of bioinformatic tools. 2009.
- 304** Injecting, sexual risk behaviors and HIV infection in young cocaine and heroin users in Spain project itinere group. 2009.
- 305** Integrase variability and susceptibility to HIV integrase inhibitors: Impact of subtypes, antiretroviral experience and duration of HIV infection. 2009.
- 306** Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. 2009.
- 307** Lack of hepatitis e virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. 2009.
- 308** Lack of significant cross-reactivity for HIV-2 immunoblots in HIV-1-infected patients. 2009.
- 309** Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus. 2009.
- 310** Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid. 2009.
- 311** Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: Influence of HIV infection. 2009.



- 312** Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy, Transmisión vertical del virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. 2009.
- 313** Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity. 2009.
- 314** New therapeutic strategies for raltegravir. 2009.
- 315** New therapies for hepatitis C virus infection. 2009.
- 316** Overestimation of liver fibrosis staging using transient elastography in patients with chronic hepatitis C and significant liver inflammation. 2009.
- 317** Pharmacogenetics of tenofovir treatment. 2009.
- 318** Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: A pharmacogenetic study. 2009.
- 319** Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients. 2009.
- 320** Raltegravir and etravirine are active against HIV Type 1 group O. 2009.
- 321** Rate and timing of hepatitis c virus relapse after a successful course of pegylated interferon plus ribavirin in hiv-infected and hiv-uninfected patients. 2009.
- 322** Reply to Pascual Pareja et al. 2009.
- 323** Role of atazanavir in the treatment of HIV infection. 2009.
- 324** Seroprevalence of HTLV-1/2 infection among native and immigrant pregnant women in Spain. 2009.
- 325** Seroreversion of Hepatitis C Virus (HCV) Antibodies in an HIV-Infected Patient despite Continuous HCV Replication. 2009.



- 326** Short communication: Transmission of hepatitis B viruses with lamivudine resistance mutations in newly diagnosed HIV individuals. 2009.
- 327** The challenge of the new H1N1 influenza A, El desafío de la nueva gripe A/H1N1. 2009.
- 328** The role of injection versus socioeconomic factors in hepatitis A virus infection among young heroin users: Implications for vaccination policies. 2009.
- 329** Tracing the HIV-1 subtype B mobility in Europe: A phylogeographic approach. 2009.
- 330** Update on HIV viral-load assays: New technologies and testing in resource-limited settings. 2009.
- 331** Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients. 2009.
- 332** Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal. 2009.
- 333** When and how to use maraviroc in HIV-infected patients. 2009.
- 334** A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. 2008.
- 335** Antiretroviral drugs and liver injury. 2008.
- 336** Antiretroviral-associated portal hypertension: A new clinical condition? Prevalence, predictors and outcome. 2008.
- 337** Association between tipranavir plasma levels and virological response in HIV-infected patients. 2008.
- 338** Autoimmune hepatitis induced by pegylated interferon in an HIV-infected patient with chronic hepatitis C. 2008.
- 339** Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel. 2008.



- 340** Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir. 2008.
- 341** Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA. 2008.
- 342** Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. 2008.
- 343** Current trends in screening across ethnicities for hypersensitivity to abacavir. 2008.
- 344** Diagnosis of HIV-1 non-B subtypes and HIV-2, Diagnóstico de las infecciones por subtipos no B del VIH-1 y por VIH-2. 2008.
- 345** Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon α 2a or α 2b. 2008.
- 346** Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients?. 2008.
- 347** Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4⁺ cells after antiretroviral therapy. 2008.
- 348** Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfecting patients receiving lamivudine as part of antiretroviral therapy. 2008.
- 349** Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: Final results of the SLOAT trial. 2008.
- 350** Efficacy of pegylated interferon plus ribavirin treatment in HIV/ hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. 2008.
- 351** Emerging drugs for hepatitis C. 2008.
- 352** Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: Frequency, predictors and outcome. 2008.
- 353** European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of chronic hepatitis B and C coinfection in HIV-infected adults. 2008.



- 354** Evaluation of eight different bioinformatics tools to predict viral tropism in different human immunodeficiency virus type 1 subtypes. 2008.
- 355** Evaluation of initial virological response to adefovir and development of adefovir-resistant mutations in patients with chronic hepatitis B. 2008.
- 356** Evidence for different susceptibility to tipranavir and darunavir in patients infected with distinct HIV-1 subtypes. 2008.
- 357** Foreword. 2008.
- 358** Genetic characterization of complex inter-recombinant HIV-1 strains circulating in Spain and reliability of distinct rapid subtyping tools. 2008.
- 359** HIV rebound after discontinuation of antiretroviral therapy increases and expands HIV-specific CD8⁺ responses but has no impact on its functionality. 2008.
- 360** HIV-1 infection in persistently HIV-1-seronegative individuals: More reasons for HIV RNA screening. 2008.
- 361** HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. 2008.
- 362** Hepatitis B in 2008: Introduction, Presentación. 2008.
- 363** Hepatitis B vaccination: An unmet challenge in the era of harm reduction programs. 2008.
- 364** Hepatitis B virus escape mutants induced by antiviral therapy. 2008.
- 365** Hepatitis B virus genotype A2 harbours an L217R polymorphism which may account for a lower response to adefovir. 2008.
- 366** Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. 2008.
- 367** Impact of antiretroviral therapy on chemokine (C-C motif) receptor 5 expression in HIV patients followed for over 2 years. 2008.



- 368** Impact of antiretroviral therapy on viral tropism in HIV-infected patients followed longitudinally for over 5 years. 2008.
- 369** Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. 2008.
- 370** Increase of non-B subtypes and recombinants among newly diagnosed HIV-1 native spaniards and immigrants in Spain. 2008.
- 371** Initial spontaneous clearance and re-infection with a distinct hepatitis C virus genotype leading to chronic hepatitis C in an HIV+ intravenous drug user [3]. 2008.
- 372** Liver cirrhosis in HIV-infected patients: Prevalence, aetiology and clinical outcome. 2008.
- 373** Liver fibrosis on account of chronic hepatitis C is more severe in HIV-positive than HIV-negative patients despite antiretroviral therapy. 2008.
- 374** Low rate of adverse hepatic events associated with fosamprenavir/ritonavir-based antiretroviral regimens. 2008.
- 375** Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. 2008.
- 376** Management of chronic hepatitis C virus infection in HIV-infected patients. 2008.
- 377** Management of hepatitis B virus co-infection on and off antiretroviral therapy. 2008.
- 378** No major differences in the functional profile of HIV gag and nef-specific CD8⁺ responses between long-term nonprogressors and typical progressors. 2008.
- 379** Opportunistic disease and mortality in patients coinfecting with hepatitis B or C virus in the Strategic Management of Antiretroviral Therapy (SMART) study. 2008.
- 380** Optimal use of maraviroc in clinical practice. 2008.
- 381** Performance of a population-based HIV-1 tropism phenotypic assay and correlation with V3 genotypic prediction tools in recent HIV-1 seroconverters. 2008.



- 382** Performance of three commercial viral load assays, versant human immunodeficiency virus type 1 (HIV-1) RNA bDNA v3.0, Cobas AmpliPrep/Cobas TaqMan HIV-1, and NucliSens HIV-1 EasyQ v1.2, testing HIV-1 non-B subtypes and recombinant variants. 2008.
- 383** Pharmacokinetics, interactions and mechanism of action of maraviroc, Maraviroc: Farmacocinética, interacciones y mecanismo de acción. 2008.
- 384** Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. 2008.
- 385** Prevalence and impact of HIV-1 protease mutation L76V on lopinavir resistance. 2008.
- 386** Prevalence of and risk factors for hepatitis B virus infection among street-recruited young injection and non-injection heroin users in Barcelona, Madrid and Seville. 2008.
- 387** Profile of patients triply infected with HIV and the hepatitis B and C viruses in the HAART era. 2008.
- 388** Reliability of rapid subtyping tools compared to that of phylogenetic analysis for characterization of human immunodeficiency virus type 1 non-B subtypes and recombinant forms. 2008.
- 389** Research Letters Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin. 2008.
- 390** Resistance in hepatitis B virus, Resistencias en el virus de la hepatitis B. 2008.
- 391** Resistance to integrase inhibitors, Resistencia a los inhibidores de la integrasa. 2008.
- 392** Response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C due to genotype 4. 2008.
- 393** Risk for immune-mediated liver reactions by nevirapine revisited. 2008.
- 394** Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. 2008.
- 395** Role of tenofovir in HIV and hepatitis C virus coinfection, Papel de tenofovir en la coinfección por el virus de la inmunodeficiencia humana y el virus de la hepatitis C. 2008.



- 396** Sexual transmission is associated with spontaneous HCV clearance in HIV-infected patients. 2008.
- 397** Spontaneous viral clearance, viral load, and genotype distribution of Hepatitis C Virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. 2008.
- 398** Statements from the 15th International Symposium on HIV and Emerging Infectious Diseases (ISHEID), Toulon, France, May 28-30, 2008. 2008.
- 399** Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola. 2008.
- 400** Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8⁺ T cells. 2008.
- 401** Switch from ritonavir-boosted to unboosted atazanavir guided by therapeutic drug monitoring. 2008.
- 402** Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements. 2008.
- 403** Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C. 2008.
- 404** Upper gastrointestinal bleeding may unmask didanosine-associated portal hepatopathy in HIV/HCV co-infected patients. 2008.
- 405** Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. 2008.
- 406** Viral resistance and genetic barrier of atazanavir, Resistencia viral y barrera genética de atazanavir. 2008.
- 407** Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?. 2008.
- 408** Adaptive cell immune response against the hepatitis C virus infection, Respuesta inmunitaria celular adaptativa frente a la infección por el virus de la hepatitis C. 2007.
- 409** Amino acid conservation in the gp41 transmembrane protein and natural polymorphisms associated with enfuvirtide resistance across HIV-1 variants. 2007.



- 410** Authors' reply to "how safe is unprotected sex between discordant couples to conceive in the highly active antiretroviral therapy era?" [2]. 2007.
- 411** Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/HCV-coinfected patients. 2007.
- 412** Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. 2007.
- 413** CD4+ T cell evolution and predictors of its trend before and after tenofovir/didanosine backbone in the presence of sustained undetectable HIV plasma viral load. 2007.
- 414** Care of patients coinfecting with HIV and hepatitis C virus: 2007 Updated recommendations from the HCV-HIV International Panel. 2007.
- 415** Changes in the distribution of hepatitis C virus (HCV) genotypes over time in Spain according to HIV serostatus: Implications for HCV therapy in HCV/HIV-coinfected patients. 2007.
- 416** Changes in the incidence of tuberculosis in a cohort of HIV-seroconverters before and after the introduction of HAART. 2007.
- 417** Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients. 2007.
- 418** Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis. 2007.
- 419** Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients. 2007.
- 420** Correlation between a phenotypic assay and three bioinformatic tools for determining HIV co-receptor use. 2007.
- 421** Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients. 2007.
- 422** Drug interactions of tipranavir, a new HIV protease inhibitor. 2007.
- 423** Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV infection: The ELADI study. 2007.



- 424** Elite HIV controllers: Myth or reality?. 2007.
- 425** Escape mutations in HIV infection and its impact on CD8+ T cell responses. 2007.
- 426** Evaluation of performance across the dynamic range of the Abbott RealTime™ HIV-1 assay as compared to VERSANT HIV-1 RNA 3.0 and AMPLICOR HIV-1 MONITOR v1.5 using serial dilutions of 39 group M and O viruses. 2007.
- 427** Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients. 2007.
- 428** Foreword. 2007.
- 429** Genetic analysis of the long terminal repeat (LTR) promoter region in HIV-1-infected individuals with different rates of disease progression. 2007.
- 430** Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia. 2007.
- 431** Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. 2007.
- 432** Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients. 2007.
- 433** Human T lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis in an HIV-positive patient coinfecting with human T lymphotropic virus type 2 following initiation of antiretroviral therapy. 2007.
- 434** Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation. 2007.
- 435** Immunizations in HIV-infected adults. 2007.
- 436** Impact of baseline protease genotype and phenotype on the response to darunavir outside clinical trials [7]. 2007.
- 437** Impact of ethnicity and HIV type 1 subtype on response to first-line antiretroviral therapy. 2007.



- 438** Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients. 2007.
- 439** Infection by the type 2 human immunodeficiency virus and types 1 and 2 human lymphotropic virus in Spain, Infección por el virus de la inmunodeficiencia humana tipo 2 y virus linfotrópicos humanos tipos 1 y 2 en España. 2007.
- 440** Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4+ and CD8+ T-cell responses to hepatitis C virus. 2007.
- 441** Influence of human T cell lymphotropic virus type 2 coinfection on virological and immunological parameters in HIV type 1-infected patients. 2007.
- 442** Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C. 2007.
- 443** Introduction of non-B subtypes among Spaniards newly diagnosed with HIV type 1 in the Canary Islands. 2007.
- 444** Is natural conception a valid option for HIV-serodiscordant couples?. 2007.
- 445** Lack of anti-HIV activity of entecavir in an HIV patient coinfecting with hepatitis B and delta viruses [3]. 2007.
- 446** Liver fibrosis stage and HCV genotype distribution in HIV-HCV coinfecting patients with persistently normal transaminases. 2007.
- 447** Management and therapy of chronic hepatitis C in HIV. 2007.
- 448** Marginal structural models application to estimate the effects of antiretroviral therapy in 5 cohorts of HIV seroconverters, Aplicación de modelos estructurales marginales para estimar los efectos de la terapia antirretroviral en 5 cohortes de seroconvertidores al virus de la inmunodeficiencia humana. 2007.
- 449** Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. 2007.
- 450** Mimotopes selected with antibodies from HIV-1-neutralizing long-term non-progressor plasma. 2007.
- 451** Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy. 2007.



- 452** Novel protease and polymerase inhibitors for the treatment of hepatitis C virus infection. 2007.
- 453** Outbreak of syphilis, but not of acute hepatitis C, among HIV-infected homosexual men in Madrid. 2007.
- 454** Poor validity of self-reported HBV vaccination among young heroin users in Spain supports the policy "don't ask, draw a blood sample, vaccinate and try to schedule another visit". 2007.
- 455** Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children. 2007.
- 456** Premature treatment discontinuation in HIV/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. 2007.
- 457** Prevalence and therapeutic significance of anti-interferon antibodies in hepatitis C virus/HIV-co-infected patients [3]. 2007.
- 458** Prevalence of HIV infection among young adult injecting and non-injecting heroin users in Spain in the era of harm reduction programmes: Gender differences and other related factors. 2007.
- 459** Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. 2007.
- 460** Prevalence of X4 tropic viruses in patients recently infected with HIV-1 and lack of association with transmission of drug resistance. 2007.
- 461** Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors. 2007.
- 462** Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors [6]. 2007.
- 463** Quantitative detection of plasma human immunodeficiency virus type 2 subtype A RNA by the NucliSens EasyQ assay (version 1.1). 2007.
- 464** Reproductive advice in HIV discordant couples, Consejo reproductivo en parejas serodiscordantes para el virus de la inmunodeficiencia humana. 2007.
- 465** Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: The PRESCO trial. 2007.



- 466** Selection of hepatitis B virus (HBV) vaccine escape mutants in HBV-infected and HBV/HIV-coinfected patients failing antiretroviral drugs with anti-HBV activity. 2007.
- 467** Short communication: Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy. 2007.
- 468** Short communication: Hospital-based surveillance for HTLV-1/2 infections in Spain. 2007.
- 469** Spanish cohort of naïve HIV-infected patients (CoRIS): Rationale, organization and initial results, Cohorte RIS de pacientes con infección por VIH sin tratamiento antirretroviral previo (CoRIS): Metodología y primeros resultados. 2007.
- 470** Spanish recommendations for proper use of enfuvirtide, Recomendaciones españolas sobre el uso adecuado de enfuvirtida. 2007.
- 471** Stavudine in antiretroviral therapy, Estavudina en el tratamiento antirretroviral. 2007.
- 472** Susceptibility of HIV-1 non-B subtypes and recombinant variants to Enfuvirtide. 2007.
- 473** Systematic review of clinical trials evaluating low doses of stavudine as part of antiretroviral treatment. 2007.
- 474** T regulatory cells and HIV infection. 2007.
- 475** Telbivudine: A new option for the treatment of chronic hepatitis B. 2007.
- 476** The implications of antiviral drugs with activity against hepatitis B virus and HIV. 2007.
- 477** Tipranavir: A new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients. 2007.
- 478** Treatment of chronic hepatitis B in HIV-infected patients in 2007. 2007.
- 479** Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. 2007.



- 480** Update on the treatment of chronic hepatitis C in HIV-infected patients. 2007.
- 481** Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards. 2007.
- 482** Antiretroviral therapy in HIV infection: How long its efficacy?, Tratamiento antirretroviral en la infección por el virus de la inmunodeficiencia humana: ¿Cuánto dura su eficacia?. 2006.
- 483** Antiviral therapy according to HIV type and subtype, Tratamiento antirretroviral según tipos y subtipos del virus de la inmunodeficiencia humana. 2006.
- 484** Autor's response [3], Respuesta de los autores. 2006.
- 485** Can the level of immunosuppression in human immunodeficiency virus-infected patients affect the reliability of human T-cell lymphotropic virus type 2 serological diagnosis?. 2006.
- 486** Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. 2006.
- 487** Chronic hepatitis C in HIV-infected patients: Those who more need therapy are those who respond less. 2006.
- 488** Coinfection with hepatitis C virus increases lymphocyte apoptosis in HIV-infected patients. 2006.
- 489** Combination of tenofovir and lamivudine versus tenofovir after lamivudine failure for therapy of hepatitis B in HIV-coinfection. 2006.
- 490** Confronting chronic hepatitis B virus infection in HIV: New diagnostic tools and more weapons. 2006.
- 491** Diagnostic, clinical and therapeutic implications of viral hepatitis in HIV-infected patients, Implicaciones diagnósticas, clínicas y terapéuticas de las hepatitis virales en el paciente infectado por el VIH. 2006.
- 492** Discordances between interpretation algorithms for genotypic resistance to protease and reverse transcriptase inhibitors of human immunodeficiency virus are subtype dependent. 2006.
- 493** Effectiveness and safety of abacavir, lamivudine, and zidovudine in antiretroviral therapy-naive HIV-infected patients: Results from a large multicenter observational cohort. 2006.



- 494** Efficacy of antiretroviral therapy in individuals infected with HIV-1 non-B subtypes. 2006.
- 495** Gene polymorphisms, isoenzyme activity, and emergence of resistance to efavirenz. 2006.
- 496** HIV and HCV coinfection, Coinfección por el VIH y el virus de la hepatitis C. 2006.
- 497** HIV entry inhibitors: Mechanisms of action and resistance pathways. 2006.
- 498** HIV entry into the cells - Mechanisms and therapeutic possibilities, Entrada del virus de la inmunodeficiencia humana en las células: Mecanismos y posibilidades terapéuticas. 2006.
- 499** HIV tropism: Diagnostic tools and implications for disease progression and treatment with entry inhibitors. 2006.
- 500** HTLV infection among young injection and non-injection heroin users in Spain: Prevalence and correlates. 2006.
- 501** High rate of proV47A selection in HIV-2 patients failing lopinavir-based HAART. 2006.
- 502** Higher risk of hyperglycemia in HIV-infected patients treated with didanosine plus tenofovir. 2006.
- 503** Immunological and virological effects of structured treatment interruptions following exposure to hydroxyurea plus didanosine. 2006.
- 504** Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. 2006.
- 505** Impact of gag sequence variability on level, phenotype, and function of anti-HIV gag-specific CD8+ cytotoxic T lymphocytes in untreated chronically HIV-infected patients. 2006.
- 506** Infections due to HIV-2 and HTLV-1/2 in Spain, Infecciones por VIH-2 y HTLV-1/2 en España. 2006.
- 507** Injecting and HIV prevalence among young heroin users in three Spanish cities and their association with the delayed implementation of harm reduction programmes. 2006.



- 508** Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C. 2006.
- 509** Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity. 2006.
- 510** Management of chronic hepatitis B and C in HIV-coinfected patients. 2006.
- 511** Molecular and epidemiological characteristics of blood-borne virus infections among recent immigrants in Spain. 2006.
- 512** Mutations affecting the replication capacity of the hepatitis B virus. 2006.
- 513** Natural polymorphisms in the protease gene modulate the replicative capacity of non-B HIV-1 variants in the absence of drug pressure. 2006.
- 514** Natural pregnancies in HIV-serodiscordant couples receiving successful antiretroviral therapy. 2006.
- 515** New findings on transcription regulation across different HIV-1 subtypes. 2006.
- 516** Overview of the pharmacogenetics of HIV therapy. 2006.
- 517** Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. 2006.
- 518** Plasma levels of atazanavir and the risk of hyperbilirubinemia are predicted by the 3435C→T polymorphism at the multidrug resistance gene 1. 2006.
- 519** Predictors of liver fibrosis in HIV-infected patients with chronic hepatitis C virus (HCV) infection: Assessment using transient elastometry and the role of HCV genotype 3. 2006.
- 520** Prevalence of the HIV-1 protease mutation I47A in clinical practice and association with lopinavir resistance. 2006.
- 521** Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients. 2006.



- 522** Reduction in liver-related hospital admissions and deaths in HIV-infected patients since the year 2002. 2006.
- 523** Regression of liver fibrosis in hepatitis C virus/HIV-co-infected patients after treatment with pegylated interferon plus ribavirin. 2006.
- 524** Reproductive options for HIV-serodiscordant couples. 2006.
- 525** Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. 2006.
- 526** Severe liver disease associated with prolonged exposure to antiretroviral drugs. 2006.
- 527** Should pregnant women be screened for T-cell type 1 lymphotropic virus?, ¿Se debería recomendar el cribado de la infección por el virus linfotrópico humano de células T de tipo 1 en las mujeres embarazadas?. 2006.
- 528** Standard of care for HCV/HIV-coinfected patients. 2006.
- 529** Suboptimal CD4 gains in HIV-infected patients receiving didanosine plus tenofovir. 2006.
- 530** Successful rescue therapy with darunabir (TMC114) in HIV-infected patients who have failed several ritonavir-boosted protease inhibitors. 2006.
- 531** Susceptibility to protease inhibitors in HIV-2 primary isolates from patients failing antiretroviral therapy. 2006.
- 532** Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients. 2006.
- 533** The calculated genetic barrier for antiretroviral drug resistance substitutions is largely similar for different HIV-1 subtypes. 2006.
- 534** Treatment of chronic hepatitis B in HIV-positive patients, Tratamiento de la hepatitis crónica B en pacientes infectados por el VIH. 2006.
- 535** Treatment of chronic hepatitis C in HIV-positive individuals: Selection of candidates. 2006.



- 536** Variability in the P6^{gag} domains of HIV-1 involved in viral budding. 2006.
- 537** Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. 2006.
- 538** Addressing current challenges in haemophilia care: Consensus recommendations of a European Interdisciplinary Working Group. 2005.
- 539** Antiretroviral recommendations may influence the rate of transmission of drug-resistant HIV type 1. 2005.
- 540** Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?. 2005.
- 541** Association of CCR5 human haplogroup E with rapid HIV type 1 disease progression. 2005.
- 542** Atazanavir: The advent of a new generation of more convenient protease inhibitors. 2005.
- 543** CD4⁺T cell recovery beyond the first year of complete suppression of viral replication during highly active antiretroviral therapy is not influenced by CD8⁺T cell activation. 2005.
- 544** Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel. 2005.
- 545** Changes in nevirapine plasma concentrations over time and its relationship with liver enzyme elevations. 2005.
- 546** Characteristics and prospects for hepatitis C therapy of an HIV-HCV coinfecting population followed at a reference HIV Center. 2005.
- 547** Clinical benefit of interventions driven by therapeutic drug monitoring. 2005.
- 548** Cohort study methodology of the ITINERE project on heroin users in three spanish cities and main characteristics of the participants, Metodología del estudio de cohortes del proyecto itinere sobre consumidores de heroína en tres ciudades españolas y características básicas de los participantes. 2005.
- 549** Complications in treating chronic hepatitis B in patients with HIV. 2005.



- 550** Current concepts in the management and treatment of hepatitis C in HIV-infected patients. 2005.
- 551** Current status of HIV-2 and HTLV-1/2 infection in Spain, Situación actual de la infección por el VIH-2 y el HTLV-1/2 en España: Luces y sombras. 2005.
- 552** Differences in the length of Gag proteins among different HIV type 1 subtypes. 2005.
- 553** Differential upregulation of CD38 on different T-cell subsets may influence the ability to reconstitute CD4⁺ T cells under successful highly active antiretroviral therapy. 2005.
- 554** Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy. 2005.
- 555** Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis c virus-coinfected patients. 2005.
- 556** Effect of ribavirin on intracellular and plasma pharmacokinetics of nucleoside reverse transcriptase inhibitors in patients with human immunodeficiency virus-hepatitis C virus coinfection: Results of a randomized clinical study. 2005.
- 557** Enfuvirtide is active against HIV type 1 group O. 2005.
- 558** Enfuvirtide, the first fusion inhibitor to treat HIV infection. 2005.
- 559** Erratum: Care of patients with chronic hepatitis B and HIV co-infection: Recommendations from an HIV-HBV International Panel (AIDS (2005) 19 (221-240)). 2005.
- 560** Erratum: Management of patients co-infected with hepatitis B virus and HIV (Lancet Infections Diseases (2005) 5 (374-382)). 2005.
- 561** Estimated extent of cross-resistance to ritonavir-boosted protease inhibitors among protease inhibitors-experienced patients: Implications for tipranavir use. 2005.
- 562** Failure of hepatitis C therapy in HIV-coinfected drug users is not due to a shift in hepatitis C virus genotype. 2005.
- 563** Genetic analysis of regulatory, promoter, and TAR regions of LTR sequences belonging to HIV type 1 non-B subtypes. 2005.



- 564** HIV-1 subtypes in Spain: A retrospective analysis from 1995 to 2003. 2005.
- 565** Hepatic and renal safety profile of tenofovir in HIV-infected patients with Hepatitis C, including patients on interferon plus ribavirin. 2005.
- 566** Hepatitis C and HIV in Spanish prisons, Hepatitis C y VIH en prisiones españolas. 2005.
- 567** Hepatitis C viremia in HIV/HCV-coinfected patients: Lower levels in presence of chronic hepatitis B. 2005.
- 568** Hepatitis C virus (HCV) genotypes and disease progression in HIV/HCV-coinfected patients. 2005.
- 569** Hepatotoxicity of antiretrovirals: Incidence, mechanisms and management. 2005.
- 570** Heterogeneous nature of HIV-1 recombinants spreading in Spain. 2005.
- 571** Impact of HIV-1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: Results of a global collaboration. 2005.
- 572** Impact of drug resistance genotypes on CD4+ counts and plasma viremia in heavily antiretroviral-experienced HIV-infected patients. 2005.
- 573** Impact of human immunodeficiency virus type 1 (HIV-1) genetic diversity on performance of four commercial viral load assays: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR v1.5, VERSANT HIV-1 RNA 3.0, and NucliSens HIV-1 QT. 2005.
- 574** Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. 2005.
- 575** Infection with human T lymphotropic virus type I in organ transplant donors and recipients in Spain. 2005.
- 576** Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. 2005.
- 577** Influence of HTLV-2 infection on hepatitis C virus replication in HIV-positive patients [2]. 2005.



- 578** Influence of hepatitis C virus infection on HIV-1 disease progression and response to highly active antiretroviral therapy. 2005.
- 579** Integrase inhibitors.2005.
- 580** Interplay between hepatitis C, liver steatosis and antiretroviral therapy in HIV-infected patients. 2005.
- 581** Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?. 2005.
- 582** Liver transplantation in HIV-HCV coinfecting candidates: What is the most appropriate time for evaluation?. 2005.
- 583** Management of patients co-infected with hepatitis B virus and HIV. 2005.
- 584** Mitochondrial DNA depletion in HIV-infected patients is more pronounced with chronic hepatitis C and enhanced following treatment with pegylated interferon plus ribavirin. 2005.
- 585** Molecular epidemiology of HTLV-2 infection among intravenous drug users in Spain. 2005.
- 586** Multicenter evaluation of the NucliSens EasyQ HIV-1 v1.1 assay for the quantitative detection of HIV-1 RNA in plasma. 2005.
- 587** New paradigms in the management of HIV and hepatitis C virus coinfection. 2005.
- 588** Nucleoside/nucleotide backbones for the treatment of HIV infection. 2005.
- 589** Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine. 2005.
- 590** Pharmacogenetics in HIV therapy. 2005.
- 591** Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. 2005.



- 592** Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: Implications for clinical management. 2005.
- 593** Prevention of nosocomial transmission of the HCV: New means for an old problem, Prevención de la transmisión nosocomial del VHC: Medios nuevos para un problema viejo. 2005.
- 594** Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. 2005.
- 595** Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: Increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. 2005.
- 596** Reductions in stavudine dose might ameliorate mitochondrial-associated complications without compromising antiviral activity. 2005.
- 597** Regulation of transcription in different HIV-1 subtypes, Regulación de la transcripción en los diferentes subtipos del VIH-1. 2005.
- 598** Relationship between drug resistance mutations, plasma viremia, and CD4⁺T-cell counts in patients with chronic HIV infection. 2005.
- 599** Resistance to nonnucleoside reverse-transcriptase inhibitors and prevalence of HIV type 1 non-B subtypes are increasing among persons with recent infection in Spain. 2005.
- 600** Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4. 2005.
- 601** Risk of selecting K65R in antiretroviral-naive HIV-infected individuals with chronic hepatitis B treated with adefovir. 2005.
- 602** Risks and benefits of antiretroviral therapy in HIV-HCV co-infected patients. 2005.
- 603** Selection of hepatitis B virus polymerase mutations in HIV-coinfected patients treated with tenofovir. 2005.
- 604** Simplification therapy with once-daily didanosine, tenofovir and efavirenz in HIV-1-infected adults with viral suppression receiving a more complex antiretroviral regimen: Final results of the EFADITE trial. 2005.
- 605** Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. 2005.



- 606** The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. 2005.
- 607** The seroepidemiology of human T-lymphotropic viruses: Types I and II in Europe: A prospective study of pregnant women. 2005.
- 608** Therapeutic drug monitoring and the inhibitory quotient of antiretroviral drugs: Can they applied to the current situation?, Monitorización terapéutica y cociente inhibitorio de los fármacos antirretrovirales: ¿son aplicables a nuestra realidad?. 2005.
- 609** Therapeutic strategies in HIV infection, Estrategias terapéuticas en la infección por el virus de la inmunodeficiencia humana. 2005.
- 610** Treatment response and drug resistance in patients infected with HIV type 1 group O viruses. 2005.
- 611** Viral response to antiretroviral therapy in a patient coinfecting with HIV type 1 and type 2. 2005.
- 612** Advances in the diagnosis and treatment of the infection by the hepatitis B virus, Avances en el diagnóstico y tratamiento de la infección por el virus de la hepatitis B. 2004.
- 613** Analyzing Sleep Abnormalities in HIV-Infected Patients Treated with Efavirenz. 2004.
- 614** Are fusion inhibitors active against all HIV variants?. 2004.
- 615** Benefits in the lipid profile after substitution of abacavir for stavudine: A 48-week prospective study. 2004.
- 616** CD38 Expression on CD8⁺ T Lymphocytes as a Marker of Residual Virus Replication in Chronically HIV-Infected Patients Receiving Antiretroviral Therapy. 2004.
- 617** CD4⁺ T-cell gain with nonnucleoside or protease inhibitors: Convenience may not always be the most convenient (multiple letters) [1]. 2004.
- 618** Care of patients with hepatitis C and HIV co-infection. 2004.
- 619** Changes in mitochondrial DNA copy number in blood cells from HIV-infected patients undergoing antiretroviral therapy. 2004.



- 620** Clinical management of treatment-experienced, HIV-infected patients with the fusion inhibitor enfuvirtide: Consensus recommendations. 2004.
- 621** Combinations of nucleoside/nucleotide analogues for HIV therapy. 2004.
- 622** Comments on the review 'Care of patients with hepatitis C and HIV co-infection' by Soriano et al. [2] (multiple letters). 2004.
- 623** Consensus conference on chronic viral hepatitis and HIV infection: Updated Spanish recommendations. 2004.
- 624** Correlation between rules-based interpretation and virtual phenotype interpretation of HIV-1 genotypes for predicting drug resistance in HIV-infected individuals. 2004.
- 625** Could mitochondrial DNA quantitation be a surrogate marker for drug mitochondrial toxicity?. 2004.
- 626** Differences in disease progression in a cohort of long-term non-progressors after more than 16 years of HIV-1 infection. 2004.
- 627** Different Viral Rebound following Discontinuation of Antiretroviral Therapy in Cases of Infection with Viruses Carrying L74V or Thymidine-Associated Mutations. 2004.
- 628** Editorial. 2004.
- 629** Enhanced HIV-specific immune responses in chronically HIV-infected patients receiving didanosine plus hydroxyurea. 2004.
- 630** Evidence for differences in the sexual transmission efficiency of HIV strains with distinct drug resistance genotypes. 2004.
- 631** Evolution of genotypic and phenotypic resistance to enfuvirtide in HIV-infected patients experiencing prolonged virologic failure. 2004.
- 632** Failure to detect human immunodeficiency virus type 1 superinfection in 28 HIV-seroconcordant individuals with high risk of reexposure to the virus. 2004.
- 633** HIV-2 and HTLV-I/II infections in Spain, Infecciones por VIH-2 y HTLV-I/II en España. 2004.



- 634** HIV-2 protease sequences of subtypes a and B harbor multiple mutations associated with protease inhibitor resistance in HIV-1. 2004.
- 635** Hepatitis C Virus (HCV) relapses after anti-HCV therapy are more frequent in HIV-infected patients. 2004.
- 636** Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin. 2004.
- 637** Hepatocellular carcinoma in HIV-infected patients: Epidemiological features, clinical presentation and outcome. 2004.
- 638** Higher efaviranz concentrations determine the response to viruses carrying non-nucleoside reverse transcriptase resistance mutations. 2004.
- 639** How effective is HAART in HCV and HIV coinfection?. 2004.
- 640** Impact of Drug Levels and Baseline Genotype and Phenotype on the Virologic Response to Amprenavir/Ritonavir-Based Salvage Regimens. 2004.
- 641** Impact of chronic hepatitis C on HIV-1 disease progression. 2004.
- 642** Impact of frequent natural polymorphisms at the protease gene on the in vitro susceptibility to protease inhibitors in HIV-1 non-B subtypes. 2004.
- 643** Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus-Infected Patients with Chronic Hepatitis C: A European Collaborative Study. 2004.
- 644** Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection. 2004.
- 645** Long-term follow-up of HIV-infected patients with chronic hepatitis C virus infection treated with interferon-based therapies. 2004.
- 646** Management of Chronic Hepatitis C in Patients Co-Infected with HIV: Focus on Safety Considerations. 2004.
- 647** Modifications in SENV DNA detection and/or SENV subtype determination over a prospective follow-up in a cohort of HIV-positive patients: Is this a moving target?. 2004.



- 648** New hopes for HIV and HCV coinfection in 2004. 2004.
- 649** Prediction of virological response to lopinavir/ritonavir using the genotypic inhibitory quotient. 2004.
- 650** Predictors of selection of K65R: Tenofovir use and lack of thymidine analogue mutations. 2004.
- 651** Predictors of severe liver fibrosis in HIV-infected patients with chronic hepatitis C [1] (multiple letters). 2004.
- 652** Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. 2004.
- 653** Predictors of virological response to Atazanavir in protease inhibitor-experienced patients. 2004.
- 654** Prevalence of HIV-1 non-B subtypes, syphilis, HTLV, and hepatitis B and C viruses among immigrant sex workers in Madrid, Spain. 2004.
- 655** Prevalence of drug resistance genotypes causing broad cross-resistance to nucleos(t)ide analogues. 2004.
- 656** Rate of infection by blood-borne viruses in active heroin users in 3 Spanish cities, Prevalencia de infección por virus de transmisión parenteral en consumidores actuales de heroína de 3 ciudades Españolas. 2004.
- 657** Resistance to HIV protease inhibitors: Mechanisms and clinical consequences. 2004.
- 658** Simplification of the antiretroviral regimens. A need to guarantee the control of long-term HIV infection, Simplificación de los regímenes antirretrovíricos. Una necesidad para garantizar el control de la infección por VIH a largo plazo. 2004.
- 659** Tenofovir-related nephrotoxicity in HIV-infected patients [2]. 2004.
- 660** The role of CD8+ T-cell response in HIV infection. 2004.
- 661** Tolerance of didanosine as enteric-coated capsules versus buffered tablets. 2004.



- 662** Triple-nucleoside regimens versus efavirenz [3] (multiple letters). 2004.
- 663** Triple-nucleoside regimens versus efavirenz.2004.
- 664** Update on hepatitis C treatment in HIV-coinfected patients. 2004.
- 665** Updated European recommendations for the clinical use of HIV drug resistance testing. 2004.
- 666** Adherence to the antiretroviral treatment. 2003.
- 667** Adherence to the antiretroviral treatment,Optimización de la adherencia al tratamiento antirretrovírico. 2003.
- 668** Avascular necrosis in HIV-infected patients receiving antiretroviral treatment: Study of seven cases. 2003.
- 669** Changes in the human immunodeficiency virus p7-p1-p6 gag gene in drug-naive and pretreated patients. 2003.
- 670** Diarrhea related to lopinavir is most often mild and not related to plasma drug levels [3]. 2003.
- 671** Effectiveness of highly active antiretroviral therapy in Spanish cohorts of HIV seroconverters: Differences by transmission category. 2003.
- 672** Erratum: Rapid assessment of phenotypic resistance to protease inhibitors in human Immunodeficiency virus type 1 group O (Journal of Clinical Microbiology (2002) 40:11 (4313-4316)). 2003.
- 673** First-line therapy and mitochondrial damage: Different nucleosides, different findings. 2003.
- 674** HIV superinfection: Clinical and biological implications,Superinfección por el virus de la inmunodeficiencia humana: Implicaciones clínicas y biológicas. 2003.
- 675** HIV-positive immigrants in the Canary Islands, Spain: Implications for public health in Eurpoe. 2003.



- 676** Hepatitis B virus infection despite receiving Lamivudine in one HIV-infected person. 2003.
- 677** High rate of resistance to antiretroviral drugs among HIV-infected prison inmates. 2003.
- 678** Human immunodeficiency virus type 1 recombinant B/G subtypes circulating in Coimbra, Portugal. 2003.
- 679** Hydroxyurea plus didanosine as maintenance therapy for HIV-infected patients on long-term successful highly active antiretroviral therapy. 2003.
- 680** Impact of hepatitis C virus (HCV) on morbidity and mortality rates among HIV-infected patients [2] (multiple letters). 2003.
- 681** Incidence of liver injury after beginning antiretroviral therapy with efavirenz or nevirapine. 2003.
- 682** Is treatment failure for hepatitis C virus infection in HIV-positive drug users associated with a shift in HCV genotypes? [3]. 2003.
- 683** Lamivudine resistance in human T-cell leukemia virus type 1 may be due to a polymorphism at codon 118 (V→I) of the reverse transcriptase (multiple letters). 2003.
- 684** Long-term outcome of HIV-infected patients with multinucleoside-resistant genotypes. 2003.
- 685** Low rate of HIV-1 codon 215 revertants in antiretroviral-experienced patients. 2003.
- 686** Mitochondrial damage by antiretrovirals: Diagnosis and monitoring, Toxicidad mitocondrial de los antirretrovirales: Diagnóstico y monitorización. 2003.
- 687** Nelfinavir plasma concentrations in patients experiencing early failure with nelfinavir-containing triple combinations. 2003.
- 688** Pegylated IFN- α 2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. 2003.
- 689** Performance of drug resistance assays in testing HIV-1 non-B subtypes. 2003.



- 690** Phenotype and Functional Characteristics of HIV-Specific Cytotoxic CD8 + T Cells in Chronically Infected Patients: Dual Effects of Highly Active Antiretroviral Therapy. 2003.
- 691** Rapid development of subacute myelopathy in three organ transplant recipients after transmission of human T-cell lymphotropic virus type I from a single donor. 2003.
- 692** Replacement of protease inhibitors by nevirapine or efavirenz in simplification and rescue interventions: Which works better?. 2003.
- 693** Replacing stavudine by abacavir reduces lactate levels and may improve lipotrophy. 2003.
- 694** Retroviral long terminal repeats: Structure and function, Secuencias largas terminales repetidas de los retrovirus: Estructura y función. 2003.
- 695** Role of baseline human immunodeficiency virus genotype as a predictor of viral response to tenofovir in heavily pretreated patients. 2003.
- 696** SENV Infection in HIV-Positive Patients: Prevalence, Subtype Characterization, and Impact on HIV Disease Progression. 2003.
- 697** Treatment of Chronic Hepatitis B in the Human Immunodeficiency Virus-Infected Patient: Present and Future. 2003.
- 698** Treatment of Chronic Hepatitis C in HIV-Infected Patients with Interferon α -2b Plus Ribavirin. 2003.
- 699** Treatment of chronic hepatitis C virus infection: We must target the virus or liver fibrosis?. 2003.
- 700** Virus load and cytotoxic responses in human immunodeficiency virus infection: What is cause and what is effect (multiple letters). 2003.
- 701** A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: The ADHOC trial. 2002.
- 702** Activity of tenofovir on hepatitis B virus replication in HIV-co-infected patients failing or partially responding to lamivudine. 2002.
- 703** Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. 2002.



- 704** Care of patients with chronic hepatitis C and HIV co-infection: Recommendations from the HIV-HCV International Panel. 2002.
- 705** Clinical impact of HTLV-1 infection in Spain: Implications for public health and mandatory screening [3]. 2002.
- 706** Decline in the rate of genotypic resistance to antiretroviral drugs in recent HIV seroconverters in Madrid. 2002.
- 707** Different degree of immune recovery using antiretroviral regimens with protease inhibitors or non-nucleosides. 2002.
- 708** Does an increase in nevirapine plasma levels cause complete virologic suppression in patients experiencing early virologic failure?. 2002.
- 709** Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. 2002.
- 710** Efficacy and safety of stavudine plus didanosine in asymptomatic HIV-infected children with plasma HIV RNA below 50,000 copies per milliliter. 2002.
- 711** Evaluation of the Abbott LCx quantitative assay for measurement of human immunodeficiency virus RNA in plasma. 2002.
- 712** Evolution of the gp41 env region in HIV-infected patients receiving T-20, a fusion inhibitor. 2002.
- 713** Factors influencing HIV progression in a seroconverter cohort in Madrid from 1985 to 1999. 2002.
- 714** Genetic mechanisms of resistance to NRTI and NNRTI. 2002.
- 715** Genetic mechanisms of resistance to protease inhibitors and entry inhibitors. 2002.
- 716** HIV-1 subtype J recombinant viruses in Spain. 2002.
- 717** High prevalence of HIV-1 subtype G and natural polymorphisms at the protease gene among HIV-infected immigrants in Madrid. 2002.



- 718** Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir. 2002.
- 719** Infection with retroviruses other than HIV-1 in Spain: A retrospective analysis for HIV-2, HTLV-I, and/or HTLV-II. 2002.
- 720** Laboratory tools for personalising treatment: Resistance and drug levels, Herramientas de laboratorio para individualizar el tratamiento: Resistencias y niveles de fármacos. 2002.
- 721** Lack of 'occult' hepatitis B virus infection in HIV-infected patients [4]. 2002.
- 722** Lipodystrophia syndrome associated with infection with human immunodeficiency virus (II). Clinical and therapeutic issues. 2002.
- 723** Lipodystrophy body-shape changes in a patient undergoing zidovudine monotherapy [4]. 2002.
- 724** Lipodystrophy syndrome associated with the human immunodeficiency syndrome virus (I). General characteristics and etiopathogenesis. 2002.
- 725** Liver biopsy in HIV-infected patients with chronic hepatitis C: Pros and cons. 2002.
- 726** Liver injury after beginning antiretroviral therapy in HIV/hepatitis C virus co-infected patients is not related to immune reconstitution. 2002.
- 727** Liver toxicity caused by nevirapine. 2002.
- 728** Management of chronic viral hepatitis in HIV-infected patients: Spanish consensus conference. 2002.
- 729** Mechanisms of resistance to antiretroviral drugs - Clinical implications. 2002.
- 730** Multicenter study of the LCx® HIV RNA Quantitative Assay - A new competitive reverse transcriptase-PCR which targets pol genomic region of HIV-1 for the measurement of type B, non-type B and group O HIV-1 RNA. 2002.
- 731** Normalization of liver enzymes in an HIV-hepatitis C virus-co-infected patient after potent antiretroviral therapy [3]. 2002.



- 732** Prevalence of G333D/E in naive and pretreated HIV-infected patients. 2002.
- 733** Prevalence of different HIV-1 subtypes in an urban clinic in Madrid.2002.
- 734** Primary lymphoma of the central nervous system and HTLV-I infection. 2002.
- 735** Rapid assessment of phenotypic resistance to protease inhibitors in human immunodeficiency virus type 1 group O. 2002.
- 736** Rate of virological treatment failure and frequencies of drug resistance genotypes among human immunodeficiency virus-positive subjects on antiretroviral therapy in Spain. 2002.
- 737** Resistance mutations in HIV-infected patients experiencing early failure with nelfinavir-containing triple combinations. 2002.
- 738** Resistance to antiretroviral agents in individuals with HIV-1 non-B subtypes. 2002.
- 739** Role of hepatitis C virus genotype in the development of severe transaminase elevation after the introduction of antiretroviral therapy. 2002.
- 740** SENC (Spanish Efavirenz vs. Nevirapine Comparison) trial: A randomized, open-label study in HIV-infected naive individuals. 2002.
- 741** Salvage treatment with lopinavir.ritonavir (Kaletra) in HIV-infected patients failing all current antiretroviral drug families. 2002.
- 742** Simplification of antiretroviral treatment - How to sustain success, reduce toxicity and ensure adherence avoiding PI use. 2002.
- 743** Spectrum of diseases in patients hospitalized with HIV infection in the HAART era,Motivo de ingreso hospitalario en pacientes con infección por el virus de la inmunodeficiencia humana en la era del tratamiento antirretroviral de gran actividad. 2002.
- 744** Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: Implications for treatment. 2002.
- 745** Weight loss in HIV-infected patients [9]. 2002.



- 746** Acute hepatitis B in a previously vaccinated patient infected by the human immunodeficiency virus. 2001.
- 747** Acute hepatitis B in a previously vaccinated patient infected by the human immunodeficiency virus [3]. 2001.
- 748** Avascular necrosis of the femoral head among patients infected with the human immunodeficiency virus on antiretroviral therapy [2], Necrosis avascular de la cabeza femoral en pacientes con infección por el virus de la inmunodeficiencia humana en tratamiento antirretrovírico. 2001.
- 749** Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. 2001.
- 750** Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: Recommendations for the European setting. 2001.
- 751** Clinical manifestations of HIV infection in the HAART era. 2001.
- 752** Comparative performance of three viral load assays on human immunodeficiency virus type 1 (HIV-1) isolates representing group M (subtypes A to G) and group O: LCx HIV RNA quantitative, AMPLICOR HIV-1 MONITOR version 1.5, and quantiplex HIV-1 RNA version 3.0. 2001.
- 753** Drug resistance in patients experiencing early virological failure under a triple combination including indinavir. 2001.
- 754** GESIDA Consensus document on the use of resistance studies in clinical practice, Documento de consenso de GESIDA sobre la utilización de los estudios de resistencias en la práctica clínica. 2001.
- 755** HIV-1 progression in hepatitis-C-infected drug users [3] (multiple letters). 2001.
- 756** HIV-1 progression in hepatitis-C-infected drug users. 2001.
- 757** Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. 2001.
- 758** Higher efavirenz plasma levels correlate with development of insomnia [1]. 2001.
- 759** Low risk of pancreatitis in HIV-infected patients on hydroxyurea plus didanosine. 2001.



- 760** Management of hepatitis C in HIV-infected persons. 2001.
- 761** Molecular evidence of homosexual transmission of HIV type 2 in Spain. 2001.
- 762** Opportunistic events shortly after beginning HAART in HIV-infected patients, Episodios oportunistas en pacientes infectados por el virus de la inmunodeficiencia humana durante los primeros 6 meses de la terapia antirretroviral de gran actividad. 2001.
- 763** Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapies. 2001.
- 764** Performance of a quadruple combination including nelfinavir plus efavirenz in naive subjects with high baseline viral load and in patients failing protease inhibitor-containing regimens [3]. 2001.
- 765** Prevalence and genetic heterogeneity of the reverse transcriptase T69S-S-X insertion in pretreated HIV-infected patients. 2001.
- 766** Prevalence of human immunodeficiency virus type 1 (HIV-1) non-B subtypes in foreigners living in Madrid, Spain, and comparison of the performances of the AMPLICOR HIV-1 MONITOR version 1.0 and the new automated version 1.5. 2001.
- 767** Primary HIV-1 drug resistance in Spain before and after the introduction of protease inhibitors. 2001.
- 768** Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. 2001.
- 769** Primary resistance to antiretroviral agents, Resistencias primarias a los antirretrovirales. 2001.
- 770** Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy. 2001.
- 771** Re: García-samaniego et al. - Hepatocellular carcinoma in patients with hcv-hiv coinfection [2] (multiple letters). 2001.
- 772** Risk factors for severe hepatic injury after introduction of highly active antiretroviral therapy. 2001.
- 773** Role of nonnucleosides in the development of HAART-related lipid disturbances [3]. 2001.



- 774** Sequencing antiretroviral drugs. 2001.
- 775** Usefulness of resistance tests to anti-retroviral agents in the clinical practice, Utilida de las pruebas de resistencias a los antirretrovíricos en la practica clínica. 2001.
- 776** Can early failure with nevirapine be rescued with efavirenz? [1]. 2000.
- 777** Cancer and human immunodeficiency virus in the era of combination therapy, Cáncer y virus de la inmunodeficiencia humana en la era de la terapia combinada. 2000.
- 778** Chronic hepatitis C in HIV-infected individuals. 2000.
- 779** Clearance of human herpesvirus type 8 viraemia in HIV-1-positive patients with Kaposi's sarcoma treated with liposomal doxorubicin. 2000.
- 780** Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. 2000.
- 781** Dynamics of dominance of a dipeptide insertion in reverse transcriptase of HIV-1 from patients subjected to prolonged therapy. 2000.
- 782** Effect of anti-retroviral therapy and prophylaxis against opportunistic diseases on survival of patients with AIDS, Efecto del tratamiento antirretrovírico y de la profilaxis para enfermedades oportunistas en la supervivencia de los pacientes con SIDA. 2000.
- 783** Efficacy and safety of didanosine and lamivudine both once daily plus indinavir in human immunodeficiency virus-infected patients. 2000.
- 784** Emergence of drug resistance mutations in human immunodeficiency virus type 2-infected subjects undergoing antiretroviral therapy. 2000.
- 785** Emergence of zidovudine resistance in HIV-infected patients receiving stavudine [1]. 2000.
- 786** HHV-8, an always intriguing, sometimes relevant herpesvirus. 2000.
- 787** Hepatitis C viraemia in HIV-HCV co-infected patients having immune restoration with highly active antiretroviral therapy. 2000.



- 788** Human immunodeficiency virus type 2 (HIV-2) in Portugal: Clinical spectrum, circulating subtypes, virus isolation, and plasma viral load. 2000.
- 789** Hydroxyurea plus didanosine as maintenance therapy after 1 year on highly active antiretroviral therapy. 2000.
- 790** In vivo fluctuation of HTLV-I and HTLV-II proviral load in patients receiving antiretroviral drugs. 2000.
- 791** Intensificación del tratamiento antirretrovírico. 2000.
- 792** Interferon plus ribavirin for chronic hepatitis C in HIV-infected patients. 2000.
- 793** Is there a role for indinavir twice-daily in clinical practice?. 2000.
- 794** Is there cross-toxicity between nevirapine and efavirenz in subjects developing rash? [4]. 2000.
- 795** Lower HIV-2 plasma viral loads may explain differences between the natural histories of HIV-1 and HIV-2 infections. 2000.
- 796** Origin and evolution of human immunodeficiency virus, Origen y evolución del virus de la inmunodeficiencia humana. 2000.
- 797** Potent activity but limited tolerance of ritonavir plus indinavir in salvage interventions. 2000.
- 798** Prevalence of HTLV infection in pregnant women in Spain. 2000.
- 799** Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. 2000.
- 800** Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. 2000.
- 801** Prevalence of novel lamivudine-resistant genotypes (E44D/A, V118I) in naive and pretreated HIV-infected individuals [3]. 2000.



- 802** Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids. 2000.
- 803** Protease gene analysis of HIV type 1 non-B subtypes in Spain. 2000.
- 804** Protease sequences from HIV-1 group M subtypes A - H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. 2000.
- 805** Quantitation of human immunodeficiency virus type 1 group O load in plasma by measuring reverse transcriptase activity. 2000.
- 806** Recombinant human immunodeficiency viruses type 1 circulating in Spain. 2000.
- 807** Retreatment for 24 vs 48 weeks with interferon- α 2b plus ribavirin of chronic hepatitis C patients who relapsed or did not respond to interferon alone. 2000.
- 808** Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. 2000.
- 809** Role of a dipeptide insertion between codons 69 and 70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance. 2000.
- 810** Salvage therapy for HIV infection: When and how. 2000.
- 811** Second Spanish Consensus on the Use of Drug Resistance Testing in Clinical Practice (Madrid, March 2000). 2000.
- 812** Simplifying antiretroviral therapy. 2000.
- 813** Terapia antirretrovírica de rescate. 2000.
- 814** Therapeutic drug monitoring for antiretroviral therapy: Usefulness and limitations. 2000.
- 815** Tolerability of Abacavir in the clinical setting. 2000.



- 816** Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded acces program, Toxicidad asociada a efavirenz en personas infectadas por el VIH incluidas en el programa de acceso expandido. 2000.
- 817** Viral load and CD4+ lymphocyte count in the era of highly active antiretroviral therapy, Carga viral y valores de linfocitos CD4+ en la era de la terapia antirretroviral altamente potente. 2000.
- 818** A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). 1999.
- 819** A rapid non-culture-based assay for clinical monitoring of phenotypic resistance of human immunodeficiency virus type 1 to lamivudine (3TC). 1999.
- 820** Association between submaximal suppression of HIV replication and use of drug combinations without protease inhibitors. 1999.
- 821** CCR5 genotype and HIV-1 infection in perinatally-exposed infants. 1999.
- 822** CCR5 genotype and human immunodeficiency virus type 1 infection in perinatally exposed infants. 1999.
- 823** Cd4+ T-lymphocytopenia, Kaposi's sarcoma, HHV-8 infection, severe seborrheic dermatitis, and onychomycosis in a homosexual man without HIV infection [4]. 1999.
- 824** Comparison of three different commercial methods for measuring plasma viraemia in patients infected with non-B HIV-1 subtypes. 1999.
- 825** Diabetes mellitus associated with protease inhibitor use. 1999.
- 826** Different outcome in the first two patients with an HIV-1 multinucleoside drug-resistant T69SSS insertion in Spain. 1999.
- 827** Different outcomes in patients achieving complete or partial viral load suppression on antiretroviral therapy. 1999.
- 828** Efficiency of drug resistance genotypic tests in specimens with low HIV viral load. 1999.
- 829** Evolution of genotypic resistance to nucleoside analogues in patients receiving protease inhibitor-containing regimens. 1999.



- 830** Hepatitis C and HTV infection: Biological, clinical, and therapeutic implications. 1999.
- 831** Higher antiviral activity of antiretroviral regimens including protease inhibitors [5]. 1999.
- 832** Human T-cell leukemia/lymphoma virus type II infection in Spain. 1999.
- 833** Human immunodeficiency virus type 2 infection in Spain. 1999.
- 834** Human immunodeficiency viruses type I subtypes circulating in Spain. 1999.
- 835** Impact of chronic liver disease due to hepatitis viruses as cause of hospital admission and death in HIV-infected drug users. 1999.
- 836** Incidence of rash and discontinuation of nevirapine using two different escalating initial doses. 1999.
- 837** Inhibidores de la proteasa del VIH: Pros y contras. 1999.
- 838** Interferon plus ribavirin in HIV-infected patients with chronic hepatitis C [1]. 1999.
- 839** Introduction of HIV drug-resistance testing in clinical practice. 1999.
- 840** Introduction to tests detecting resistance to antiretroviral agents in the clinical practice, Introducción de las pruebas de detección de resistencias a los antirretroviricos en la práctica clínica. 1999.
- 841** Management of chronic hepatitis C in HIV-infected patients. 1999.
- 842** Multiple drug resistance genotype causing failure of antiretroviral treatment in an HIV-infected patient heavily exposed to nucleoside analogues. 1999.
- 843** Patterns of response (CD4 cell count and viral load) at 6 months in HIV-infected patients on highly active antiretroviral therapy. 1999.



- 844** Phylogeny of HIV type 1 group O isolates based on env gene sequences. 1999.
- 845** Presence of genotypic resistance in nucleoside analogue-treated HIV-1-infected patients with undetectable viral load. 1999.
- 846** Prevalence of HIV infection and risk habits in heroin takers of Barcelona, Madrid and Sevilla (Spain). An example of the advantages of focusing studies on drug-takers in spite of intravenous drug users, Prevalencia de infección por el virus de la inmunodeficiencia humana y de conductas de riesgo entre los consumidores de heroína de Barcelona, Madrid y Sevilla: Un ejemplo de las ventajas de centrar los estudios en los consumidores y no sólo en los usuarios por vía intravenosa. 1999.
- 847** Prevalence of drug resistance mutations in Spain among both naive and pretreated patients. 1999.
- 848** Primary cavity-based lymphoma and HIV infection, Linfoma primario de cavidades e infección por VIH. 1999.
- 849** Sociodemographic and psychological variables influencing adherence to antiretroviral therapy. 1999.
- 850** Spanish consensus conference on drug resistance testing in clinical practice [16]. 1999.
- 851** Stavudine resistance: An update on susceptibility following prolonged therapy. 1999.
- 852** Strongyloidiasis and HTLV-I infection, Estrongiloidiasis e infección HTLV-1. 1999.
- 853** The hepatitis C virus: after the track of the human immunodeficiency virus, El virus de la hepatitis C: tras los pasos del virus de la inmunodeficiencia humana. 1999.
- 854** The incorporation of resistance tests to antiretroviral drugs to clinical practice, Incorporación del examen de resistencias a los antirretrovirales en la práctica clínica. 1999.
- 855** Usefulness of genotypic analysis of resistance to nucleoside analogues in the clinical setting. 1999.
- 856** V3-loop and nef gene sequences of HIV-1 isolates from a hemophiliac cohort with long-term non-progressive infection. 1999.
- 857** What dual protease inhibitor combination for salvage therapies? [8]. 1999.



- 858** Admissions and deceases in an HIV unit before and after protease inhibitors. 1998.
- 859** Admissions and mortality in a HIV unit before and after protease inhibitors, Ingresos y defunciones en una Unidad de VIH antes y después de los inhibidores de la proteasa. 1998.
- 860** Analysis of pol gene heterogeneity, viral quasispecies, and drug resistance in individuals infected with group O strains of human immunodeficiency virus type 1. 1998.
- 861** Antiretroviral treatment: When and how start, Tratamiento antirretroviral: Cuando empezar y con que?. 1998.
- 862** Combine antiretroviral therapy for prevention of vertical HIV-1 transmission, Terapia antirretroviral combinada para la prevencion de la transmision vertical de la infeccion por el VIH-1. 1998.
- 863** Efficacy and tolerance of the combination AZT, DDC and saquinavir in HIV infected patients [2], Eficacia y tolerancia de la combinacion AZT, DDC y saquinavir en pacientes infectados por el virus de la inmunodeficiencia humana. 1998.
- 864** Efficacy of combining zidovudine plus didanosine in patients with and without previous exposure to zidovudine, Eficacia de la combinacion de zidovudina y didanosina en pacientes con y sin exposicion previa a zidovudina. 1998.
- 865** Efficacy of ritonavir in HIV+ patients pretreated with nucleoside analogues, Eficacia del ritonavir en pacientes VIH+ previamente tratados concentration analogos de nucleosidos. 1998.
- 866** Epidemiología molecular del virus de la inmunodeficiencia humana. 1998.
- 867** Evidence of nef truncation in human immunodeficiency virus type 2 infection. 1998.
- 868** False positives for HIV using commercial viral load quantification assays [3]. 1998.
- 869** Genetic analysis of human immunodeficiency virus type 2 strains from Spain. 1998.
- 870** Genotypic and phenotypic resistance to stavudine after long-term monotherapy. 1998.
- 871** HTLV-I infection in Spain [1]. 1998.



- 872** Hepatotoxicity after introduction of highly active antiretroviral therapy [8]. 1998.
- 873** Horizontal and vertical transmission of human immunodeficiency virus type 1 dual infections caused by viruses of subtypes B and C. 1998.
- 874** How many HIV's are there?, Cuántos VIH existen?. 1998.
- 875** Interacciones farmacológicas en los pacientes infectados por el virus de la inmunodeficiencia humana. 1998.
- 876** Interrelationship between the duration of HIV infection, the viral load and the CD4+ lymphocyte count, Interrelación entre la duración de la infección por el virus de la inmunodeficiencia humana, la viremia plasmática y la cifra de linfocitos CD4+. 1998.
- 877** LTR and tat variability of HIV-1 isolates from patients with divergent rates of disease progression. 1998.
- 878** Lack of benefit of protease inhibitors on HCV viremia in HIV-infected patients [3]. 1998.
- 879** Long-term suppression of HIV replication in patients with sustained benefit on zidovudine monotherapy [10]. 1998.
- 880** Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: Evidence of variabilities in levels of virion-associated RT. 1998.
- 881** Nephrolithiasis in HIV-infected patients treated with indinavir [1]. 1998.
- 882** Performance of an ultrasensitive assay to test undetectable viral load specimens using the branched DNA assay [8]. 1998.
- 883** Phylogenetic analysis of HIV type 2 strains from Portugal. 1998.
- 884** Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and antiretroviral-experienced HIV-infected patients in Spain. 1998.
- 885** Quantitative p24 antigenaemia for monitoring response to antiretroviral therapy in HIV-1 group O-infected patients. 1998.



- 886** Regression of invasive AIDS-related Kaposi's sarcoma following antiretroviral therapy. 1998.
- 887** Seven new cases of HIV-2 infection detected in Madrid in 1996 and 1997, Siete casos nuevos de infección por VIH-2 reconocidos en Madrid en 1996 y 1997. 1998.
- 888** The decline in CD4+ T lymphocytes as a function of the duration of HIV infection, age at seroconversion, and viral load. 1998.
- 889** The ultrasensitive NASBA assay for quantifying HIV-1 viral load. 1998.
- 890** Tropism, coreceptor use, and phylogenetic analysis of both the V3 loop and the protease gene of three novel HIV-1 group O isolates. 1998.
- 891** Virologic levels for HIV before and after the introduction of protease inhibitors, Valores de viremia por VIH antes y después de la introducción de los inhibidores de la proteasa. 1998.
- 892** Virological failure and adherence to antiretroviral therapy in HIV-infected patients [7]. 1998.
- 893** A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. 1997.
- 894** A pilot study on the efficacy of escalating dosage of alpha-interferon for chronic hepatitis C in HIV-infected patients. 1997.
- 895** Addition of lamivudine to the drug regimen in patients with advanced HIV disease on nucleoside therapy. 1997.
- 896** Addition of lamivudine to the drug regimen in patients with advanced HIV disease on nucleoside therapy [4]. 1997.
- 897** Antiretroviral therapy and resistance. 1997.
- 898** Characterization of the reverse transcriptase of a human immunodeficiency virus type 1 group O isolate. 1997.
- 899** Chemokine receptors and HIV-2 [11]. 1997.



- 900** Co-infection with several HCV genotypes enhances liver damage in patients with chronic hepatitis C [3]. 1997.
- 901** Comparison of three different commercial methods for quantification of plasma HIV RNA in clinical specimens. 1997.
- 902** Epidemiology of viral hepatitis, Epidemiología de las hepatitis víricas. 1997.
- 903** Evidence of HIV-2 infection in Equatorial Guinea (Central Africa): Partial genetic analysis of a B subtype virus. 1997.
- 904** Genetic analysis of an HIV type 2 subtype B virus from a spanish individual with AIDS. 1997.
- 905** HTLV-1 infection in a prisoner: the first case in Spain, Infección por HTLV-1 en un paciente recluso: primer caso en España. 1997.
- 906** Human T-Cell lymphotropic virus infection in pregnant women in Spain. 1997.
- 907** Human immunodeficiency virus type 1 serotypes in Madrid, Spain, Serotipos del virus de la inmunodeficiencia humana tipo 1 en Madrid. 1997.
- 908** Infection with the human immunodeficiency virus (HIV) in the geriatric age: Epidemiologic and clinical study in 42 patients in the Madrid Community, Infección por el VIH en la edad geriátrica: Estudio epidemiológico y clínico en 42 pacientes de la Comunidad de Madrid. 1997.
- 909** Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. 1997.
- 910** Influence of time and storage conditions on plasma HIV viral load measurements. 1997.
- 911** Lack of antiretroviral effect of alpha-interferon in HIV-infected patients treated for chronic hepatitis C [2]. 1997.
- 912** Lack of emergence of genotypic resistance to stavudine after 2 years of monotherapy [10]. 1997.
- 913** Lack of genotypic resistance to stavudine (d4T) after 2 years of monotherapy. 1997.



- 914** Mycosis fungoides and Sezary syndrome are not associated with HTLV-I infection: An international study. 1997.
- 915** Non-progressors with zidovudine: Rate and main features, Frecuencia y características de los pacientes tratados con zidovudina y ausencia de progresión de la infección por VIH. 1997.
- 916** Nosocomial infection with methicillin resistant Staphylococcus aureus in 14 human immunodeficiency virus infected patients, Brote nosocomial de infección por Staphylococcus aureus resistente a metilicina en 14 pacientes infectados por el virus de la inmunodeficiencia humana. 1997.
- 917** Outcome in a cohort of long-term non-progressors in Madrid: virological and immunological findings. 1997.
- 918** Quantification of HIV viremia, Cuantificación de la viremia por VIH. 1997.
- 919** Quantitation of viremia in patients infected with human immunodeficiency virus with different degrees of immunosuppression, Cuantificación de la viremia en pacientes infectados por el virus de la inmunodeficiencia humana con diferentes grados de inmunodepresión. 1997.
- 920** Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy [13]. 1997.
- 921** Reliability of a New Recombinant Immunoblot Assay (RIBA HIV-1/ HIV-2 SIA) as a Supplemental (Confirmatory) Test for HIV-1 and HIV-2 Infections. 1997.
- 922** Reliability of a new recombinant immunoblot assay (RIBA HIV-1/HIV-2 SIA) as a supplemental (confirmatory) test for HIV-1 and HIV-2 infections. 1997.
- 923** Resistance to antiretroviral drugs, Resistencia a los fármacos antirretrovirales. 1997.
- 924** Rising incidence of human T-cell leukaemia/lymphoma virus type II in Spanish drug users [12]. 1997.
- 925** Safety and efficacy of two different triple drug combinations in which either lamivudine or didanosine were administered with stavudine plus indinavir [9]. 1997.
- 926** Short-term response to indinavir in patients with advanced HIV disease with prior heavy exposure to nucleoside analogues [7]. 1997.
- 927** Significance of indeterminate reactivity to human T-Cell lymphotropic virus in western blot analysis of individuals at risk. 1997.



- 928** Species-specific identification of intestinal microsporidiosis by polymerase chain reaction, Identificación específica de microsporidiosis intestinales en pacientes HIV-positivos mediante la reacción en cadena de la polimerasa. 1997.
- 929** Tratamiento antirretrovírico y resistencias. 1997.
- 930** Visceral leishmaniasis in patients infected with the human immunodeficiency virus. 1997.
- 931** Absence of HIV-2 infection in Basque seamen frequently travelling to the West African coast. 1996.
- 932** Antiretroviral therapy for HIV infection [2], Tratamiento antirretroviral frente al virus de la inmunodeficiencia humana [2]. 1996.
- 933** Carga vírica y monitorización del tratamiento antirretrovírico. 1996.
- 934** Circulating HIV-1 serotypes in Spain. 1996.
- 935** Circulating hepatitis C virus genotypes in Spain. The Hepatitis/HIV Spanish Study Group. 1996.
- 936** Clinical significance of the genetic variability of the human immunodeficiency virus, Importancia clínica de la variabilidad genética del virus de la inmunodeficiencia humana. 1996.
- 937** Colony-stimulating factors and HIV-related neoplasms, Factores estimulantes de colonias y neoplasias asociadas al VIH. 1996.
- 938** Correlation between serological and genetic methods for typing hepatitis C virus. 1996.
- 939** Development of a multiplex PCR assay for the simultaneous detection and discrimination of HIV-1, HIV-2, HTLV-I and HTLV-II. 1996.
- 940** Epidemiology of HIV-2 infection in Spain. 1996.
- 941** Epidemiology of HTLV-I infection in Spain. 1996.



- 942** Epidemiology of human T-lymphotropic virus type II (HTLV-II) infection in Spain. 1996.
- 943** Fever, cough and x-ray pulmonary condensation in an HIV-positive patient. Kaposi's sarcoma, Fiebre, tos y condensación pulmonar radiológica en un paciente VIH+. 1996.
- 944** Fever, cough, and radiologic lung condensation in an HIV+ patient, Fiebre, tos y condensación pulmonar radiológica en un paciente VIH+. 1996.
- 945** First case of HIV-1 group O infection in Spain. 1996.
- 946** First two cases of HIV-1 group O infection in Spain, Descripción de los dos primeros casos de infección por VIH-1 grupo O en España. 1996.
- 947** HIV infection, tuberculous hepatosplenic abscesses and steroid therapy, Abscesos hepatoesplénicos tuberculosos, infección por virus de la inmunodeficiencia humana y tuberculosis multirresistente. 1996.
- 948** HTLV-1 infection in Spanish drug abusers [2], INFECCION POR HTLV-1 EN DROGADICTOS ESPAÑOLES [2]. 1996.
- 949** Hepatitis C viraemia in HIV-infected patients [3]. 1996.
- 950** Hepatitis C virus genotypes in different risk populations in Spain [4]. 1996.
- 951** High alcohol intake and slow progression to AIDS. 1996.
- 952** High alcohol intake and slow progression to AIDS [1]. 1996.
- 953** High rate of indeterminate reactivity to HTLV in Western blot analysis of Spanish blood donors [4]. 1996.
- 954** Impact of antiretroviral therapy on hepatitis C viraemia in HIV-infected patients. 1996.
- 955** Interferon treatment for chronic hepatitis C in patients infected by the immunodeficiency virus, TRATAMIENTO DE LA HEPATITIS CRÓNICA C CON INTERFERÓN EN PACIENTES INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA. 1996.



- 956** Interferon α for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. 1996.
- 957** Interferon-alpha for chronic hepatitis C in HIV-infected persons. 1996.
- 958** Lack of evidence for viral clearance in children born to HIV-infected mothers [8]. 1996.
- 959** Long-term survival in an HIV-immunosuppressed patient treated with foscarnet, Supervivencia prolongada en un paciente inmunodeprimido por VIH tratado con foscarnet. 1996.
- 960** Long-term zidovudine responders: Is there still rationale for HIV monotherapy? [4]. 1996.
- 961** Manejo de las hepatitis víricas en los pacientes infectados por el virus de la inmunodeficiencia humana. 1996.
- 962** Monitorization of antiretroviral treatment, Monitorización del tratamiento antirretroviral. 1996.
- 963** New concepts in antiretroviral therapy against HIV, TRATAMIENTO ANTIRRETROVIRAL FRENTE AL VIH. 1996.
- 964** Nucleotide sequence and restriction fragment-length polymorphism analysis of human T-cell lymphotropic virus type II (HTLV-II) in Southern Europe: Evidence for the HTLV-IIa and HTLV-IIb subtypes. 1996.
- 965** Prevalence of hepatitis C virus genotypes in spanish drug addicts with chronic hepatitis C, Prevalencia de los genotipos del virus de la hepatitis C en drogadictos españoles con hepatitis crónica C. 1996.
- 966** Prevalence of zidovudine-resistant HIV-1 among rapid progressors [2]. 1996.
- 967** Propuesta de una escala de puntuación para decidir la opción terapéutica en la hepatitis crónica C en pacientes infectados por VIH. 1996.
- 968** Rapid and slow disease progression in HIV-1 infected persons in Madrid, Spain, Progresión rápida y lenta de la infección por el virus de la inmunodeficiencia humana tipo 1 en una población de sujetos seropositivos de Madrid. 1996.
- 969** Rationale for early antiretroviral therapy in patients with CD4 cell counts \geq 500 cells/mm³. 1996.



- 970** Recent spread of human T lymphotropic virus type II among injecting drug users in Spain [1]. 1996.
- 971** Reliability of a screening assay for the simultaneous detection of antibodies to HIV-1/2 and HTLV-I/II [3]. 1996.
- 972** Serial dilutions on synthetic peptide-based assays can resolve dual seroreactivity to HIV-1 and HIV-2 [1]. 1996.
- 973** Sexual transmission of two different HCV types causing acute hepatitis C [3]. 1996.
- 974** Treatment against human immunodeficiency virus in terms of the viral load: yes or no?, Tratamiento frente al virus de la inmunodeficiencia humana en función de la carga viral: sí o no?. 1996.
- 975** Very late presentation of vertically transmitted HIV-I infection. 1996.
- 976** Viral load in relation to clinical outcome in HIV-infected children [6]. 1996.
- 977** env Gene characterization of the first HIV type 1 group O Spanish isolate. 1996.
- 978** env gene diversity of HIV type 1 isolates from Spain. 1996.
- 979** ANTIRETROVIRAL THERAPY AGAINST HIV. 1995.
- 980** Avoiding false-negative results for HTLV-II using new serological assays. 1995.
- 981** Characteristics of chronic delta hepatitis in patients with HIV infection, Características de la hepatitis crónica Delta en pacientes infectados por el VIH. 1995.
- 982** Efficacy and safety of α -interferon treatment for chronic hepatitis C in HIV-infected patients. 1995.
- 983** Endocarditis of the pulmonary valve in parenteral drug addicts, Endocarditis sobre válvula pulmonar en adictos a drogas por vía parenteral. 1995.



- 984** Epidemiology of HTLV-I/II infection in Spain. 1995.
- 985** HIV without AIDS but no AIDS without HIV, VIH sin SIDA, pero no SIDA sin VIH. 1995.
- 986** HIV-1 group O, VIH-1 grupo O. 1995.
- 987** HTLV-I and HTLV-II in Africans [1]. 1995.
- 988** HTLV-I infection in Spain. Analysis of 24 cases identified until November, 1994. Spanish Group for the Study of HTLV-I/II), Infección por HTLV-I en España. Análisis de 24 casos identificados hasta noviembre de 1994. Grupo Español para el Estudio del HTLV-I/II. 1995.
- 989** HTLV-II infection in Spain. Analysis of 113 cases identified until November, 1994. Spanish Group for the Study of HTLV-I/II), Infección por HTLV-II en España. Análisis de 113 casos identificados hasta noviembre de 1994. Grupo Español para el Estudio del HTLV-I/II. 1995.
- 990** High rate of co-infection with different hepatitis C virus subtypes in HIV-infected intravenous drug addicts in Spain. 1995.
- 991** Human lymphotropic virus type I (HTLV-I), El virus linfotrópico humano de tipo I (HTLV-I). 1995.
- 992** Morbidity and mortality associated with chronic viral hepatopathy in patients infected with the human immunodeficiency virus, Morbilidad y mortalidad asociadas a hepatopatía crónica viral en pacientes infectados por el virus de la inmunodeficiencia humana. 1995.
- 993** More severe course of delta hepatitis in HIV-infected patients [L] [5]. 1995.
- 994** Phylogenetic relationship and geographic distribution of multiple human T- cell lymphotropic virus type II subtypes. 1995.
- 995** Prevalence of human T-cell lymphotropic virus type 1 (HTLV-1) and HTLV-2 infection among Spanish drug users measured by HTLV-1 assay and HTLV-1 and - 2 assay. 1995.
- 996** Prevalence of infection by human T-cell leukemia virus types I and II in southern Spain. 1995.
- 997** Rapid progression to AIDS in a patient with infection from a strain of syncytium forming HIV-1, PROGRESION RAPIDA A SIDA EN UN PACIENTE INFECTADO CON UNA CEPA DEL VIH-1 FORMADORA DE SINCITIOS. 1995.



- 998** Residual risk of retrovirus transmission by transfusions, Riesgo residual de transmisión de retrovirus por transfusiones. 1995.
- 999** Strategies for the prevention of human immunodeficiency virus infection, Estrategias para la prevención de la infección por el virus de la inmunodeficiencia humana. 1995.
- 1000** The actual risk of retrovirus transmission from transfusions, Riesgo actual de transmisión de retrovirus por transfusiones. 1995.
- 1001** The quantification of human immunodeficiency virus viremia in patients with rapid and slow progression of the disease, Cuantificación de la viremia por el virus de la inmunodeficiencia humana en pacientes con progresión rápida y lenta de la enfermedad. 1995.
- 1002** The rapid and slow progression of HIV infection, Progresión rápida y lenta de la infección por VIH. 1995.
- 1003** Type 2 human immunodeficiency virus infection (HIV-2) in Spain: analysis of the first 50 cases. Spanish Group for the Study of HIV-2, Infección por el virus de la inmunodeficiencia humana tipo 2 (VIH-2) en España: análisis de los primeros 50 casos. Grupo Español para el Estudio del VIH-2. 1995.
- 1004** AIDS in the elderly people [3], SIDA EN EL ANCIANO [3]. 1994.
- 1005** Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome [1]. 1994.
- 1006** Absence of evidence of retroviral infection in idiopathic CD4+ T-lymphocytopenia syndrome [1]. 1994.
- 1007** Aplastic anemia after non-A, non-B, non-C hepatitis. 1994.
- 1008** Assessment of allopurinol plus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV. 1994.
- 1009** CD4+ T-lymphocytopenia in HIV-infected patients receiving interferon therapy for chronic hepatitis C [1]. 1994.
- 1010** Diagnosis of perinatal infection by the human immunodeficiency virus, Diagnóstico de la infección perinatal por el virus de la inmunodeficiencia humana. 1994.
- 1011** Enhanced diagnostic efficiency of the polymerase chain reaction by co-amplification of multiple regions of HIV-1 and HIV-2. 1994.



- 1012** Evaluation of a New Fluorescence Immunoassay for CD4+ and CD8+ T Cell Counts in Clinical Samples. 1994.
- 1013** Gastrointestinal leishmaniasis in human immunodeficiency virus-infected patients: Report of five cases and review. 1994.
- 1014** Gastrointestinal leishmaniasis in patients infected with the human immunodeficiency virus, Leishmaniasis gastrointestinal en pacientes infectados por el virus de la inmunodeficiencia humana. 1994.
- 1015** HIV-2, EI VIH-2. 1994.
- 1016** HTLV-I, EI HTLV-I. 1994.
- 1017** HTLV-II, EI HTLV-II. 1994.
- 1018** High morbidity and mortality associated with non-AIDS defining conditions in HIV-infected patients in Spain. 1994.
- 1019** High morbidity and mortality associated with non-AIDS defining conditions in HIV-infected patients in Spain [1]. 1994.
- 1020** High morbidity and mortality of chronic viral liver disease in HIV-infected individuals in Spain. 1994.
- 1021** Misdiagnosis of pancreatitis in patients receiving treatment with pentavalent antimonial agents. 1994.
- 1022** Misdiagnosis of pancreatitis in patients receiving treatment with pentavalent antimonial agents [7]. 1994.
- 1023** Serological diagnosis of HIV-1 infection, Diagnóstico serológico de la infección por VIH-1. 1994.
- 1024** Serum activity of the lactate dehydrogenase enzyme in patients with human immunodeficiency virus infection, Actividad sérica de la enzima láctico deshidrogenasa en pacientes con infección por el virus de la inmunodeficiencia humana. 1994.
- 1025** Study of 164 episodes of infectious endocarditis in drug addicts: comparison of HIV positive and negative patients, Estudio de 164 episodios de endocarditis infecciosa en drogadictos: comparación entre pacientes VIH positivos y negativos. 1994.



- 1026** Syndrome of hypersensitivity to phenytoine, SINDROME DE HIPERSENSIBILIDAD A FENITOINA. 1994.
- 1027** The treatment and prophylaxis of the main infections associated to the human immunodeficiency virus [1], TRATAMIENTO Y PROFILAXIS DE LAS PRINCIPALES INFECCIONES ASOCIADAS AL VIH [1]. 1994.
- 1028** Therapy with interferon in HIV-infected patients with chronic viral hepatitis, TRATAMIENTO CON INTERFERON EN LOS PACIENTES CON HEPATITIS CRONICA VIRICA INFECTADOS POR EL VIH. 1994.
- 1029** Viral replication in patients with multiple hepatitis virus infections. 1994.
- 1030** Xanthomonas maltophilia endocarditis in an AIDS patient, Endocarditis por Xanthomonas maltophilia en un paciente con SIDA. 1994.
- 1031** A multicenter study of infection with human immunodeficiency virus type-2 (HIV-2) in Spain (1991). The Spanish Group for the Study of HIV-2, Estudio multicéntrico de la infección por el virus de la inmunodeficiencia humana tipo 2 (VIH-2) en España (1991). Grupo Español para el Estudio del VIH-2. 1993.
- 1032** Changes in the spectrum of the diseases in patients hospitalized with HIV infection, Cambios en el espectro de enfermedades en pacientes hospitalizados con infección por VIH. 1993.
- 1033** Combined therapy in HIV infection, TERAPIA COMBINADA EN LA INFECCION POR VIH. 1993.
- 1034** Diagnosis of visceral leishmaniasis in HIV-infected individuals using peripheral blood smears. 1993.
- 1035** Evaluation of various criteria for the interpretation of western blot for the diagnosis of human immunodeficiency virus infection. Spanish Group for the Study of HIV-2, Evaluación de diferentes criterios de interpretación del Western blot para el diagnóstico de la infección por el virus de la inmunodeficiencia humana. Grupo Español para el Estudio del VIH-2. 1993.
- 1036** Favorable evolution of brain toxoplasmosis treated with doxycylin and pirimetamine[1], EVOLUCION FAVORABLE DE LA TOXOPLASMOSIS CEREBRAL TRATADA CON DOXICICLINA Y PIRIMETAMINA[1]. 1993.
- 1037** HIV-2 Infection in high-risk individuals in Spain. 1993.
- 1038** HTLV-I and transfusions, HTLV-I y transfusiones. 1993.
- 1039** Immunodeficiency and opportunistic processes in the absence of human immunodeficiency virus infection, Inmunodeficiencia y procesos oportunistas en ausencia de infección por el virus de la inmunodeficiencia humana. 1993.



- 1040** Kussmaul respiration and abdominal pain secondary to metabolic acidosis in AIDS patients with disseminated Mycobacterium avium complex infection receiving clofazimine [3]. 1993.
- 1041** Misdiagnosis of HTLV-II infection using HTLV-I screening assays [7]. 1993.
- 1042** Multicenter study of HTLV-I and HTLV-II infection in Spain. Spanish Group for the Study of HTLV-II/II Infection, Análisis multicéntrico de la infección por HTLV-I y HTLV-II en España. Grupo Español para el Estudio de la Infección HTLV-I/II. 1993.
- 1043** Pneumonia by the type 1 herpes simplex virus in a patient with AIDS, NEUMONIA POR VIRUS DEL HERPES SIMPLE TIPO 1 EN UN PACIENTE CON SIDA. 1993.
- 1044** Prophylaxis of pneumocystis carinii pneumonia [7]. 1993.
- 1045** Pyomyositis in patients with HIV infection [5]. 1993.
- 1046** Retrovirus: diagnostic tests and their interpretation (I). Generalities and infection by HIV-1, Retrovirus: pruebas diagnósticas y su interpretación (I). Generalidades e infección por el VIH-1. 1993.
- 1047** Retrovirus: diagnostic tests and their interpretation (II). HIV-2, HTLV-I, and HTLV-II infection, Retrovirus: pruebas diagnósticas y su interpretación (II). Infección por el VIH-2, el HTLV-I y el HTLV-II. 1993.
- 1048** Retroviruses and autoimmune diseases, Retrovirus y enfermedades autoinmunes. 1993.
- 1049** Serologic activity against retrovirus in patients with Sjögren syndrome, Reactividad serológica frente a retrovirus en pacientes con síndrome de Sjögren. 1993.
- 1050** Treatment and prophylaxis of the principal infections associated to the human immunodeficiency virus, TRATAMIENTO Y PROFILAXIS DE LAS PRINCIPALES INFECCIONES ASOCIADAS AL VIRUS DE LA INMUNODEFICIENCIA HUMANA. 1993.
- 1051** ACUTE POLYRADICULOMYELITIS BY CYTOMEGALOVIRUS IN A PATIENT WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME. 1992.
- 1052** An esophageal ulcer due to cytomegalovirus in a female patient infected with the human immunodeficiency virus without serious immunosuppression: is this an acquired immunodeficiency syndrome?, Ulcera esofágica por citomegalovirus en una paciente infectada por el virus de la inmunodeficiencia humana sin inmunodepresión grave: es un síndrome de inmunodeficiencia adquirida?. 1992.
- 1053** Aspergillus hepatosplenic abscesses and chylous ascites: successful treatment with fluconazole. 1992.



- 1054** Clinical syndromes in HIV infection (1st of 2 parts), Síndromes clínicos en la infección por el VIH (primera de dos partes). 1992.
- 1055** Clinical syndromes in HIV infection (part 2), Síndromes clínicos en la infección por el VIH (segunda de dos partes). 1992.
- 1056** Evidence of infection by HIV-2 in Madrid (1991), Evidencia de infección por el VIH-2 en Madrid (1991). 1992.
- 1057** Fatal varicella hepatitis in a patient with AIDS. 1992.
- 1058** HIV-1 and HIV-2 in Spain [3]. 1992.
- 1059** HIV-2 infection in Spain: Report of the first 34 cases [8]. 1992.
- 1060** Human immunodeficiency virus infection in seronegative subjects: myth or reality?, Infección por el virus de la inmunodeficiencia humana en sujetos seronegativos: mito o realidad?. 1992.
- 1061** Interferon in chronic hepatitis in patients with the human immunodeficiency virus, INTERFERON EN LA HEPATITIS CRÓNICA DE SUJETOS INFECTADOS POR EL VIRUS DE LA INMUNODEFICIENCIA HUMANA: SI O NO?. 1992.
- 1062** Lethal meningitis caused by varicella-zoster virus in a patient with AIDS, Hepatitis fulminante por virus varicelazoster en un paciente con SIDA. 1992.
- 1063** Multicenter study of the prevalence of type 2 human immunodeficiency virus infection in Spain (1990), Estudio multicéntrico de la prevalencia de infección por el virus de la inmunodeficiencia humana tipo 2 en España (1990). 1992.
- 1064** Multifocal bone tuberculosis in one AIDS patient [1]. 1992.
- 1065** Multifocal splenic abscesses in AIDS-related tuberculosis. 1992.
- 1066** Multifocal tubercular osteitis in a female patient infected with the human immunodeficiency virus, Osteítis tuberculosa multifocal en una paciente infectada por el virus de la inmunodeficiencia humana. 1992.
- 1067** Prevalence of antibodies against hepatitis C virus in HIV positive subjects from different risk groups, Prevalencia de anticuerpos frente al virus de la hepatitis C en sujetos VIH positivos de diferentes grupos de riesgo. 1992.



- 1068** The prevention of AIDS,La prevención del SIDA.1992.
- 1069** The seroepidemiology of infection with the human immunodeficiency virus type 2 (HIV-2) in Spain (1990). The Spanish Group for the Study and Follow-up of HIV-2 Infection,Seroepidemiología de la infección por virus de la inmunodeficiencia humana de tipo 2 (VIH-2) en España (1990). Grupo Español para el estudio y seguimiento de la infección por VIH-2.1992.
- 1070** The tuberculous of AIDS. A new tuberculosis?,LA TUBERCULOSIS DEL SIDA: UNA NUEVA TUBERCULOSIS?. 1992.
- 1071** The usefulness of the polymerase chain reaction in the diagnosis of human immunodeficiency virus infection,Utilidad de la reacción en cadena de la polimerasa en el diagnóstico de la infección por virus de la inmunodeficiencia humana.1992.
- 1072** Viral etiology of Sjögren's syndrome,Etiología viral del síndrome de Sjögren.1992.
- 1073** Abdominal tuberculosis in patients with acquired immunodeficiency syndrome,Tuberculosis abdominal en los pacientes con síndrome de inmunodeficiencia adquirida.1991.
- 1074** Multifocal splenic abscesses caused by Mycobacterium tuberculosis in HIV-infected drug users [3]. 1991.
- 1075** Prevention of transfusional infection caused by human immunodeficiency virus,Prevención de la infección transfusional por el virus de la inmunodeficiencia humana.1991.
- 1076** Serologic and genomic markers of the hepatitis C virus in transfusion recipients with non-A, non-B hepatitis,Marcadores serológicos y genómicos del virus de la hepatitis C en receptores de transfusiones con hepatitis no A no B.1991.
- 1077** Silent human immunodeficiency virus infections,Infecciones silentes por el virus de la inmunodeficiencia humana.1991.
- 1078** The etiology of Kaposi's sarcoma,Etiología del sarcoma de Kaposi.1991.
- 1079** The evidence of human immunodeficiency virus infection in the seronegative subjects of high-risk groups,Evidencia de infección por el virus de la inmunodeficiencia humana en sujetos de colectivos de alto riesgo que son seronegativos.1991.
- 1080** Treatment of HIV: Present outlook,TRATAMIENTO DE LA INFECCION POR VIH: PERSPECTIVA ACTUAL. 1991.
- 1081** Tropical spastic paraparesis and HTLV-I. The first case in Spain,Paraparesia espástica tropical y HTLV-I. Primer caso en España.1991.



- 1082** Visceral leishmaniasis: Main therapeutic agents and new prospects, LEISMHANIASIS VISCERAL: PRINCIPALES AGENTES TERAPEUTICOS Y NEUVAS PERSPECTIVAS. 1991.
- 1083** Which HIV-infected individuals develop AIDS faster?, Qué individuos infectados por el VIH progresan más rápidamente a SIDA?. 1991.
- 1084** AIDS and Kaposi sarcoma pre-1979 (II). 1990.
- 1085** Diagnosis of human retrovirus infections by techniques of nucleic acid amplification/hybridization, Diagnóstico de la infección por retrovirus humanos mediante técnicas de amplificación/hibridación de ácidos nucleicos. 1990.
- 1086** Evaluation of different tests to detect antigen and antibodies for the diagnosis of HIV primoinfection, EVALUACION DE DIFERENTES PRUEBAS PARA LA DETECCION DE ANTIGENO Y ANTICUERPOS EN EL DIAGNOSTICO DE LA PRIMOEINFECCION POR EL VIH. 1990.
- 1087** Evidence of HTLV-1 infection in different groups at risk in Barcelona, Evidencia de infección por el HTLV-1 en diferentes colectivos de riesgo de Barcelona. 1990.
- 1088** HTLV-1 and malignant hemopathies in Barcelona, HTLV-Y HEMOPATIAS MALIGNAS EN BARCELONA. 1990.
- 1089** HTLV-I in patients from Barcelona with connective tissue diseases, neurologic demyelinating diseases and lymphoproliferative syndromes, Investigación del HTLV-I en pacientes de Barcelona con conectivopatías, enfermedades neurológicas desmielinizantes y síndromes linfoproliferativos. 1990.
- 1090** Primary infection caused by human immunodeficiency virus: clinical and serologic aspects of 7 cases, Primoinfección por el virus de la inmunodeficiencia humana: aspectos clínicos y serológicos de 7 casos. 1990.
- 1091** Risk factors for HIV-1 infection in parenteral drug users. 1990.
- 1092** Sexual transmission of hepatitis C virus and its relation with hepatitis B virus and HIV. 1990.
- 1093** The evaluation of heterosexual transmission of the human immunodeficiency virus by nucleic acid amplification technics, Evaluación de la transmisión heterosexual del virus de la inmunodeficiencia humana por técnicas de amplificación de ácidos nucleicos. 1990.
- 1094** The evidence for HTLV-1 infection in different risk groups in Barcelona, La evidencia de infección por HTLV-1 en diferentes colectivos de riesgo en Barcelona. 1990.
- 1095** The human immunodeficiency virus type 2 (HIV-2), El virus de la inmunodeficiencia humana tipo II (VIH-2). 1990.



- 1096** The recurrence of a gynecological neoplasm as a solitary thyroid nodule, Recidiva de neoplasia ginecológica como nódulo tiroideo solitario. 1990.
- 1097** Type 1 human T lymphotropic virus (HTLV-I), El virus humano linfotrópico T de tipo 1 (HTLV-I). 1990.
- 1098** A prospective study of 57 cases of Mediterranean boutonuse fever. 1989.
- 1099** ANTI HTLV-1 ANTIBODIES IN PATIENTS WITH MULTIPLE TRANSFUSIONS. 1989.
- 1100** Adenosine deaminase and boutonuse fever, Adenosín-desaminasa y fiebre botonosa. 1989.
- 1101** Antibodies against HTLV-1 in patients undergoing multiple transfusions, Investigación de anticuerpos frente al HTLV-1 en pacientes politransfundidos. 1989.
- 1102** Chylous ascites and nephrotic syndrome, Ascitis quilosa y síndrome nefrótico. 1989.
- 1103** Complications in Mediterranean boutonuse fever: prospective study of 78 patients, Complicaciones en la fiebre botonosa mediterránea: estudio prospectivo de 78 pacientes. 1989.
- 1104** Detection of antibodies against human immunodeficiency virus type II using a third-generation ELISA, Detección de anticuerpos frente al virus de la inmunodeficiencia humana tipo II por ELISA de tercera generación. 1989.
- 1105** Difficulties in research on antibodies to HTLV-I, Dificultades en la investigación de anticuerpos frente al HTLV-I. 1989.
- 1106** Evidence of infection by type 2 (HIV 2) human immunodeficiency virus in heroin addicts in Barcelona, Evidencia de infección por el virus de la inmunodeficiencia humana tipo 2 (VIH 2) en heroinómanos de Barcelona. 1989.
- 1107** HTLV-1 infection in Barcelona, Infección par le HTLV-1 à Barcelone. 1989.
- 1108** Human immunodeficiency virus type 2 in Spain. 1989.
- 1109** Human immunodeficiency virus type 2 infection in Western Africans living in Catalonia, Infección por el virus de la inmunodeficiencia humana tipo 2 en africanos occidentales residentes en Catalunya. 1989.



- 1110** Infection by HTLV-1 in heroin addicts in Barcelona, Infección por el HTLV-1 en heroinómanos de Barcelona. 1989.
- 1111** Predictive value of neopterin in boutonneuse fever. 1989.
- 1112** Serological markers in human immunodeficiency virus infection, Marcadores serológicos en la infección por el virus de la inmunodeficiencia humana. 1989.
- 1113** Should antibodies against HTLV-1 be analyzed in Spanish blood donations?, Deben investigarse los anticuerpos frente al HTLV-1 en las donaciones de sangre españolas?. 1989.
- 1114** The risk of retrovirus transmission by blood transfusions, Riesgo de transmisión de retrovirus por transfusiones de sangre. 1989.
- 1115** ANTIGEN AND ANTIBODIES OF HUMAN IMMUNODEFICIENCY VIRUS IN PARENTERAL DRUG-ABUSERS - CORRELATION WITH THE CLINICAL STAGE. 1988.
- 1116** Detection of anti-p24 in patients with acquired immunodeficiency syndrome, Detección de anti-p24 en pacientes con síndrome de inmunodeficiencia adquirida. 1988.
- 1117** Difficulties of investigation of antibodies against human immunodeficiency virus type 2 using ELISA, Dificultades en la investigación de anticuerpos frente al virus de la inmunodeficiencia humana de tipo 2 por ELISA. 1988.
- 1118** Human immunodeficiency virus antigens and antibodies in parenteral drug addicts: correlations with a clinical study, Antígeno y anticuerpos del virus de la inmunodeficiencia humana en adictos a drogas por vía parenteral: correlación con el estadio clínico. 1988.
- 1119** Hypodipsia in the elderly, Hipodipsia en el anciano. 1988.
- 1120** Myoglobin-latex in the early diagnosis of acute myocardial infarction, Mioglobina-látex en el diagnóstico temprano del infarto agudo de miocardio. 1988.
- 1121** Routine study of the human immunodeficiency virus antigen in blood banks, Investigación rutinaria del antígeno del virus de la inmunodeficiencia humana en los bancos de sangre. 1988.
- 1122** Serum adenosine deaminase activity in Mediterranean spotted fever, Actividad sérica de la adenosín deaminasa en la fiebre botonosa mediterránea. 1988.
- 1123** Lichen planus and hepatopathy, Liquen plano y hepatopatía. 1987.



CURRÍCULUM VÍTAE NORMALIZADO

2476498e78ec462b67028f841867fcbd

1124 htlv-1.